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Summary 
Progressive loss of mesencephalic dopaminergic (mesDA) neurons is the main 
pathological feature of Prakinson’s Disease. The homeobox transcription factors, 
Engrailed-1 and Engrailed-2, are essential for survival and long-term maintenance of 
this neuronal population. In mutant embryos, null for both genes, the mesDA neurons 
are generated and start to express their neurotransmitter phenotype, but fail to 
differentiate and die during midgestation. The mice, heterozygous for Engrailed-1 and 
homozygous null for Engrailed-2, suffer a Parkinson’s Disease-like postnatal 
degeneration of their nigral DA neurons. Prior studies had shown that the Engrailed-
deficient mesDA neurons die by apoptosis, evident from activation of caspase-3 and 
presence of pyknotic nuclei. The subject of this study was to elaborate more on the 
molecular pathway of death and to find out the mechanisms of survival by interfering 
with this process. 
In this work, I demonstrate that reduction in expression of Engrailed in mesDA 
neurons results in a higher sensitivity to mitochondrial apoptotic insult. The increased 
vulnerability to treatment with MPTP or specific inhibitors of Bcl-2 and Bcl-XL causes 
release of cytochrome C from the mitochondrial inter-membrane space into the cytosol 
and subsequent activation of caspases. I also show that the Engrailed deficiency results 
in increased expression of P75 neurotrophin receptor, which is causal to death of the 
neurons. The death of Engrailed double mutant mesDA neurons, as a direct result of 
high expression of P75, can be inhibited by application of TrkB/C-specific 
neurotrophins, BDNF, NT4 or NT3, by siRNA knockdown (of P75) or by addition of 
an inhibiting antibody for P75. The rescue effect of these survival factors is diminished 
by concurrent treatment of the primary cell cultures with an inhibitor of the 
extracellular signal regulated kinase1/2 (Erk1/2) pathway. Additionally, there is an 
inverse correlation between expression of P75 and phosphorylation of Erk1/2, 
suggesting that Erk1/2 deactivation is critical to the death signaling of P75. 
This study shows a connection between the etiology of PD, exemplified by 
mitochondrial instability, and the dose dependent survival effect of the Engrailed 
genes. In addition to causing mitochondrial vulnerability, the absence of engrailed 
genes activates a death pathway, instigated by the high expression of P75 and 
inhibition of activation of Erk1/2 pathway. 
  
 
VI 
Zusammenfassung 
Progressiver Verlust der mesencephalen dopaminergen (mesDA) Neurone ist das 
bedeutenste pathologische Kennzeichen von Morbus Parkinson. Die Homedomänen-
Transkriptionsfaktoren Engrailed-1 und Engrailed-2 sind notwendig für das Überleben 
dieser neuronalen Population. In Mausembryonen die eine Nullmutation beider Gene 
tragen, entstehen diese Neurone und beginnen ihren Neurotransmittertyp zu exprimieren, 
differenzieren jedoch nicht und sterben während der Schwangerschaft ab. Mäuse, die 
heterozygot für Engrailed-1 und homozygot für Engrailed-2 sind, erleiden eine Parkinson-
ähnliche postnatale Degeneration ihrer nigralen DA Neurone. Vorhergehende Studien 
haben gezeigt, dass die mesDA Neurone Apoptose durchlaufen, deutlich sichtbar an der 
Aktivierung von Caspase-3 und des Vorkommens von pyknotischen Nuklei. Das Ziel 
dieser Arbeit war die weitere Erforschung dieses molekularen Wegs zum Zelltod, der 
Mechanismus und Möglichkeiten, diesen zu stören oder zu unterbrechen. 
In dieser Arbeit zeige ich, dass die Reduktion der Expression von Engrailed in mesDA 
Neuronen zu einer höheren Empfindlichkeit gegnüber mitochondrialer apoptotischer 
Störung führt. Die höhere Sensivität gegenüber einer Gabe von MPTP oder spezifischen 
Inhibitoren für Bcl-2 und Bcl-XL verursacht die Freisetzung von Cytochrom C aus dem 
mitochondrialen inter-Membranraum in das Zytosol und eine darauffolgende Aktivierung 
von Caspasen. Ich zeige ausserdem, dass der Verlust von Engrailed zu einer erhöhten 
Expression von P75 Neurotrophin Rezeptor führt, der den Zelltod dieser Neurone 
verursacht. Der Tod der mesDA Neurone in Engrailed Doppelmutanten als eine Ursache 
von hoher P75 Expression kann durch TrkB/C spezifische Neurotrophine wie BDNF, NT4 
oder NT3, durch siRNA knockdown von P75 oder durch Antikörper gegen P75 verhindert 
werden.Der positive Effekt dieser Überlebensfaktoren wird durch eine Behandlung der 
primären Zellkulturen mit einem Inhibitor des Signalweges der extrazellulären 
Signalkinase 1/2 (Erk1/2) verringert.Zusätzlich besteht eine inverse Korrelation zwischen 
der Expression von P75 und der Phosphorylierung von Erk1/2, die es wahrscheinlich 
erscheinen lässt, dass die Erk1/2 Deaktivierung notwendig für den Signalweg von P75 ist. 
Diese Studie zeigt eine Korrelation zwischen der Ätiologie von Morbus Parkinson, 
dargestellt durch eine mitochondriale Instabilität, und des dosisabhängigen 
Überlebenseffekts der Engrailed Gene. Ausser eine mitochondriale Verwundbarkeit 
hervorzurufen, führt die Abwesenheit der Engrailed Gene zur Aktivierung eines 
apoptotischen Signalwegs, der durch die hohe Expression von P75 und der Inhibition der 
Aktivierung des Erk1/2/ Signalwegs ausgelöst wird. 
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1. General Introduction 
 
Mesencephalic dopaminergic (mesDA) neurons are the main source of dopamine in 
the central nervous system. The specific loss of mesDA neurons of the substantia nigra 
pars compacta (SNpc) is the main characteristic of one of the most prominent 
neurodegenerative disorders, Parkinson’s disease (PD). The homeodomain 
transcription factors Engrailed-1 (En1) and Engrailed-2 (En2) play pivotal roles in 
differentiation survival and maintenance of the mesDA neurons during the embryonic 
development and throughout adulthood. In mice lacking both Engrailed genes, mesDA 
neurons are generated and start expressing their neurotransmitter phenotype, but they 
die by apoptosis between E12 and E14, the stages when the expression of Engrailed in 
wild type embryos sets in (Alberi et al., 2004; Simon et al., 2001). The intermediate 
genotypes between complete lack of the Engrailed genes and wild type show various 
degrees of cell loss in the mesDA system. Most interestingly, mice heterozygous null 
for Engrailed-1 and homozygous null for Engrailed-2 (En1+/-;En2-/-), which are 
viable and fertile, exhibit a progressive degeneration, specific to the nigral DA neurons 
within the first three months after birth, resulting in a phenotype reminiscent of PD. 
Although the causes of vulnerability and degeneration of mesDA neurons are still 
unknown, the evidence like involvement of the death receptors and their ligands, 
mitochondrial dysfunction and an increase in activation of caspases suggest the 
extrinsic and intrinsic pathways of apoptosis as the executioners of neuronal cell death. 
Mitochondria is a point of convergence for several deleterious processes, involved in 
pathogenesis of PD. Reduced activity of mitochondrial complex-I and production of 
reactive oxygen species (ROS) has been observed in postmortem brain tissue of PD 
patients and can cause specific loss of nigral mesDA neurons in three major 
neurotoxin-based models of the disease, MPTP, Rotenone and 6-OHDA (Schober, 
2004). This inhibition results in permeability of the mitochondrial membrane and 
release of pro-apoptotic molecules, like cytochrome C, into the cytoplasm and 
activation of caspases, leading to apoptotic cell death. In animal models of PD, This 
effect could be ablated by high expression of Bcl-2 and Bcl-XL the anti-apoptotic 
members of the Bcl-2 family (Vila et al., 2001; Yang et al., 1998). 
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Neuronal cell death can be a result of neurotrophin deficiency. Action of the 
neurotrophins, consisting of NGF, BDNF, NT4/5 and NT3, is mediated via a set of 
specific tyrosine kinase receptors (TrkA, B, C) and a common receptor, P75 
(P75NTR/NGFR). While the Trk receptors signal survival(Lu et al., 2005), P75 can 
have a survival or apoptotic function, dependent on the cellular context and the 
molecular form of the ligand(Lu et al., 2005). The pro-survival role of neurotrophins 
and their receptors has been mainly attributed to the downstream effect of 
phosphotydil inositol-3 kinase (PI3K) and the extracellular receptor kinase 1/2 
(Erk1/2) pathway(Krieglstein et al., 2002), whereas apoptosis by P75 alone is triggered 
by phosphorylation of JNK and of the BH3-only members of the Bcl-2 family(Bhakar 
et al., 2003). 
In this work, I have studied the mechanism of loss of the Engrailed-deficient mesDA 
neurons, in correlation with the death machinery of P75, one of its transcriptional 
regulatory targets, and in the context of etiology of PD, mitochondrial dysfunction and 
apoptosis. 
 
2. Development of mesDA Neurons and Transcription Factors 
2.1. Early Development 
 
The central nervous system develops from the neural ectoderm. After gastrulation, 
thickening of the neural ectoderm results in formation of neural plate. This process 
takes place under the inductive control of signaling molecules released from the 
notochord and the dorsal mesoderm. The ectoderm’s default cell fate is neural but the 
neural differentiation is mainly inhibited by activity of the bone morphogenic protein 
(BMP) pathway and to some degree, members of the FGF and Wnt families. The 
neural fate is a result of blocking of these inhibitory forces or, in other words, de-
repression. Blocking of the BMP pathway by factors like follistatin, noggin and 
chordin or inhibition of the Wnt pathway by the activity of FrzB, dickkopf, and 
Cerberus can induce neural fate. During neurulation, the rostrocaudal neural plate is 
formed and bent to shape the neural groove; then, it folds up on its anterioposterior 
axis and eventually closes to form the neural tube (Smith and Schoenwolf, 1997). 
Then, by the rostrocaudal patterning, the neural tube is subdivided into four major 
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parts of forebrain, 
midbrain, hindbrain, 
and the spinal cord 
(Lumsden and 
Krumlauf, 1996; 
Rubenstein and 
Beachy, 1998; 
Rubenstein et al., 
1998). This 
subdivision relies 
on the pattern of 
expression of 
transcription factors 
within the neural 
ectoderm (Prakash and Wurst, 2004). After rostrocaudal patterning, under the 
ventralizing induction of the sonic hedgehog (SHH) and the dorsalizing induction of 
BMPs, the neural tube becomes dorsoventrally polarized (Simon et al., 2003). 
At this stage, the expression of genes in the boundary between midbrain and hindbrain 
forms the midbrain-hindbrain organizing structure (MHO), which is essential to the 
fate of mesDA neurons by regulation of further development of this region and 
controlling generation of specific cell populations in the ventral midbrain and rostral 
hindbrain (Liu and Joyner, 2001). One of the first positional signals to appear is the 
drosophila orthodenticle protein, Otx2, which is expressed in the epiblast and in the 
anterior visceral endoderm before gastrulation (Simeone et al., 2002). The expression 
of Otx2 becomes progressively limited to the anterior ectoderm and from E7 onward, 
sharply defines the region of forebrain and midbrain (Broccoli et al., 1999). In the 
Otx2 mutant mice, the forebrain and midbrain regions are deleted (Acampora et al., 
1995). At the same time, similar to Otx2, the expression of Gbx2 becomes limited 
from all three germ layers of the posterior embryo to the anterior hindbrain by E8.5. 
Since in Gbx2-/- mutants, domain of Otx2 expands posteriorly during early somite 
stages, it is likely that Gbx2 defines the caudal border of Otx2 domain (Millet et al., 
1999).  In mice embryos, deficient for both Otx2 and Gbx-2 genes, the temporal 
expression of Fgf8 and other genes in the midbrain-hindbrain region is unaltered but 
 
Figure-1: Schematic view of an E12 embryo; Induction of mesDA neurons 
by Fgf8 and SHH and approximate domains of expression of the factors, 
involved in regional identity of the midbrain and specification of mesDA 
neurons. 
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the position of expression of this set of genes is shifted to the anterior region of the 
neuroectoderm, suggesting that the expression of Otx2 and Gbx2 is required only for 
the proper positioning, and not the induction, of the midbrain/hindbrain organizer 
MHO (Li and Joyner, 2001). 
Between E8 and E9, functionally equivalent transcription factors, Pax2 and Pax5, are 
expressed in a domain around the Otx2/Gbx2 boundary (Bouchard et al., 2000) and are 
required in a gene-dose dependent manner for proper development of the midbrain and 
the cerebellum (Urbanek et al., 1997). Then Wnt1, a homolog of the drosophila 
segmentation gene, wingless, is expressed within the Pax-2 domain and is restricted to 
the Otx2 positive midbrain cells. The main function of Wnt1 is development of the 
midbrain and in Wnt1 mutant mice, the entire midbrain and cerebellum is lost 
(McMahon et al., 1992). Wnt1 regulates the expression of the Engrailed and their 
expression domains overlap (Bally-Cuif et al., 1992). 
The next factors, important in early development of mesDA neurons, are the Engrailed 
genes with Engrailed-1, being expressed in the entire mesencephalon-met encephalon 
and the Engrailed-2 expression domain being around the Otx2/Gbx2 boundary (Davis 
and Joyner, 1988). In early stages, the En1 mutant mice, show cerebellar and 
patterning defects. These effects are minor in the En2-deficient mice (Millen et al., 
1994) (Wurst et al., 1994). Later on, expression of the Engrailed genes in the mesDA 
neurons imposes a gene dose-dependent survival effect on these neurons (Simon et al., 
2001). Two other structurally related proteins, Lmx1a and Lmx1b, encoding a LIM 
homeodomain-containing transcription factor, are expressed after E9.5. Lmx1b is 
expressed in the caudal forebrain, midbrain, and hindbrain but its expression domain 
eventually becomes restricted to the Wnt1 and Fgf8 expression domain at the isthmus 
(Adams et al., 2000). On the other hand, the expression of Lmx1a is specific to 
dopaminergic progenitor cells and essential for induction of mesDA neurons 
(Andersson et al., 2006).  
The mesDA neurons are induced by a combinatorial effect of the fibroblast growth 
factor 8 (Fgf8), which is locally produced at the mid/hindbrain boundary and in the 
rostral forebrain, and the sonic hedgehog (SHH), which is expressed along the ventral 
neural tube (Ye et al., 1998)(Fig. 1). Mice, lacking Fgf8, have gastrulation defects and 
do not have DA neurons (Ye et al., 1998). Also, the Fgf8 soaked beads can induce 
ectopic generation of midbrain and cerebellar structures along with expression of 
Introduction 
 
 
6 
marker genes in the diencephalon of the chick brain (Crossley et al., 1996; Liu and 
Joyner, 2001).  Studies in zebra fish confirm the pivotal role of Fgf8 in formation of 
isthmic organizer and development of the region around it(Guo et al., 1999; Reifers et 
al., 1998).  
SHH is considered a general ventralizing signal in the CNS. The amino terminal 
product of SHH autoproteolysis (SHH-N), produced by the floor plate, can induce 
different cell types within the neural tube in a dose dependent manner and is capable of 
inducing dopaminergic neurons in vitro (Hynes et al., 1995; Wang et al., 1995). SHH 
can also coordinate tissue size and shape in addition to cell type identity (Agarwala et 
al., 2001). 
The factors involved during the transition period, between the time of induction of 
dopaminergic progenitor dells and when mesDA neurons become post mitotic, are 
mainly unknown. Two homeodomain proteins, important during this period, are 
Lmx1a and Msx1, which are induced by SHH. The role of Lmx1a has been extensively 
studied and shown to be important in formation of roof plate and dorsal-ventral 
patterning of the neural tube (Kruger et al., 2002; Millonig et al., 2000). While Lmx1a 
and Msx1, both, are selectively expressed in the DA progenitor cells, only the 
expression of Lmx1a can induce ectopic dopaminergic cells in chick embryos and can 
cause expression of Msx1(Andersson et al., 2006). The essential function of Lmx1a, as 
an intrinsic determinant of the mesDA neurons has been confirmed by its ability to 
differentiate embryonic stem cells into mesDA neurons. The evidence, including 
ability of Lmx1a to induce dopaminergic neurons of correct identity, expressing Nurr1, 
En1, Pitx3, Lmx1b and DAT, and also reduction of mesDA neurons, when Lmx1a is 
knocked down by RNA interference, show that Lmx1a is required and sufficient for 
differentiation of mesDA neurons from DA progenitor cells (Andersson et al., 2006).  
After induction by Fgf8 and SHH, the mesDA neurons are generated and detectable by 
the rate-limiting enzyme of the dopamine production, tyrosine hydroxylase (TH). 
There are time differences between generation of the subpopulations of mesDA 
neurons, with higher proportions of the substantia nigra pars compacta (SNpc) and 
retrorubral field (RRF) being generated earlier (E11) than ventral tegmentum (VT). 
Around the same time, the neurons start innervating their respective targets in the basal 
ganglia and forming two of the most important DA pathways of the brain. Innervation 
of axons from VT to nucleus accumbens and the olfactory tubercle forms the 
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mesolimbic pathway while neurons of SNpc project their axons to the dorsal striatum, 
forming the nigrostriatal pathway (Nelson et al., 1996). 
At this stage, the expression of Lmx1b, Nurr1, Pitx3, and the Engrailed genes (En1 and 
En2), all crucial survival factors (Simon et al., 2003; Wallen and Perlmann, 2003), in 
is detectable in mesDA neurons (Fig. 3). These factors represent at least three 
molecular cascades, essential for survival of the postmitotic mesDA neurons 
throughout the life of a species (Fig. 2)(Smidt et al., 2000). 
 
2.2. Post-mitotic Transcription Factors 
2.2.1. Nurr-1 
 
Nurr-1 is a member of the orphan nuclear receptors. The structural analysis of the 
ligand-binding domain shows that there is neither a cavity within the structure nor a 
binding site for co-activators, meaning that Nurr1 is ligand independent (Wang et al., 
2003). The expression of Nurr1 starts in the ventral midbrain at E10.5, around the time 
 
Figure-2: Time of expression and main function of transcription factors in development of the 
midbrain and mesDA neurons. Dashed lines represent expression in the region and not 
necessarily in the mesDA neurons. 
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the mesDA neurons express TH and become post mitotic (Zetterstrom et al., 1996). 
One of the main functions of Nurr1 is the control over synthesis and storage of 
dopamine in the midbrain. Mice, lacking Nurr1, do not express TH (Castillo et al., 
1998) due to a direct trans-activation of the promoter of TH (Kim et al., 2003). 
Furthermore, expression of Nurr1 in dopaminergic MN9D cells increases DA content 
and the expression of aromatic L-amino acid decarboxylase (AADC) and vesicular 
monoamine transporter-2 (VMAT2).  In mesDA cells of Nurr1 knockout embryos 
AADC and VMAT2 are deregulated (Hermanson et al., 2003; Smits et al., 2003). 
Study of the Nurr1 knockout mice also show that at P0, the dopaminergic phenotypic 
markers are absent from the mesDA neurons, while mesDA specific transcription 
factors like Pitx3, Engrailed1/2 and Lmx1b are present (Perlmann and Wallen-
Mackenzie, 2004). 
Nurr1 is important for migration of the mesDA neurons and their innervation to their 
respective forebrain targets (Perlmann and Wallen-Mackenzie, 2004; Wallen et al., 
1999; Witta et al., 2000). Additionally, the Nurr1 heterozygous null mice show a 
postnatal, age dependent loss of nigral neurons resulting in reduced dopamine levels in 
the striatum and motor dysfunction (Jiang et al., 2005). An important factor, 
deregulated in mesDA neurons of Nurr1 knock-out mice is Ret, a subunit of receptors 
for glial derive neurotrophin factor (GDNF) (Baloh et al., 1997; Robertson and Mason, 
1997; Wallen et al., 2001). GDNF promotes survival of mesDA neurons in various in 
vivo and in vitro conditions, including against neurotoxin treatment or the naturally 
occurring postnatal cell death (Burke et al., 1998; Clarkson et al., 1995; Tomac et al., 
1995). Although Nurr1 is considered a postmitotic survival factor for the mesDA 
neurons, its expression in neuronal stem cells, can induce a general dopaminergic 
phenotype and in combination with expression of Pitx3 can result in terminal 
maturation of ES cell cultures into midbrain dopaminergic phenotype (Martinat et al., 
2006). 
Nurr1 represents a strong link between developmental paradigms and pathogenesis of 
PD. Several screenings of DNA from PD patients has provided a direct link of Nurr1 
to PD.  In such a study, about 10% of the familial PD cases had a hetero-duplex 
variation in the exon-1 of the Nurr1 gene while the patients with sporadic PD were 
unaffected (Le et al., 2003). In another study, a homozygous polymorphism of intron-6 
was found in 9.5% of the familial cases and 4.2% of the sporadic patients (in 
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comparison to 0.9% for control individuals) (Xu et al., 2002). The heterozygote 
polymorphism of the same site has been associated with increased risk of PD (Zheng et 
al., 2003). In addition to the genetic studies, Nurr1 has been linked to the animal 
models of PD by studies showing a direct correlation between the level of expression 
of Nurr1 and resistance to MPTP induced injury (Le et al., 1999; Lee et al., 2002). 
Taken together, these studies show that Nurr1 is crucial for long term survival of 
mesDA neurons, in addition to being important in the terminal differentiation and 
neurotransmitter identity of these neurons.  
 
2.2.2. Pitx3 
 
The expression of the paired-like homeodomain transcription factor 3 (Pitx3) in the 
CNS is limited to the ventral midbrain and specifically to the mesDA neurons, starting 
between E11.5 and E12.5 (Smidt et al., 1997). Since Pitx3 is also expressed in the 
developing lens, deletion of a region upstream of the 5’ UTR of the Pitx3 gene results 
in Aphakia, characterized by small eyes and lack of a lens and anterior segment 
structures, caused by an arrest of lens development around E10-E11 (Semina et al., 
2000). In the Pitx3 knockout (Aphakia) mice, loss of mesDA neurons is mostly in the 
rostral and lateral regions and at P0, the loss is almost exclusive to the SNpc and, with 
the exception of the cells bordering with SNpc, the VTA neurons remain unaltered. 
The loss of nigral neurons does not cause significant motor deficits, despite the 
considerable reduction in the dopamine level of the striatum (Nunes et al., 2003; Smidt 
et al., 2004; Smits et al., 2005). 
Since the entire population of mesDA neurons is present in Aphakia mouse at E11.5 
(the onset of expression of Pitx3), it is unlikely that Pitx3 is involved in proliferation 
or migration of these neurons and the specific nigral loss in these mice is due to a 
defect in terminal differentiation (Smidt et al., 2004). The specificity of the function of 
Pitx3 to the DA neurons of SNpc is more evident from the ES cells, expressing Pitx3, 
which show an up-regulation of the genes more specific to this region and not for the 
entire population of mesDA neurons. An example of such genes is aldehyde 
dehydrogenase 2 (AHD2), which has its highest expression level in the nigral DA 
neurons. This is in contrast to the expression of Nurr1 in ES cells, which lacks this 
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specificity and is relevant to all midbrain DA markers (Chung et al., 2005). In addition 
to its role in differentiation, Pitx3 controls the expression of TH in the nigral DA 
neurons, by activation of the TH promoter through direct interaction with a single 
high-affinity binding site within the promoter (Maxwell et al., 2005) (Lebel et al., 
2001).  
 
2.2.3. Lmx1b 
 
Lmx1b and Pitx3 are part of the same molecular pathway, since in the mice, 
homozygous null for Lmx1b, Pitx3 expression is lost. The TH expression in the 
mesDA neurons of these mice is unaltered (Burbach et al., 2003). In addition to its 
importance in limb and kidney development (Chen et al., 1998; Kania et al., 2000), the 
member of the LIM homeodomain family, Lmx1b, is also critical in development and 
survival of the mesDA neurons. The expression of Lmx1b in mesDA neurons starts 
around E7.5 and continues throughout the embryonic development into adulthood 
(Burbach et al., 2003). The expression of Lmx1b is maintained by Fgf8 and defines the 
localization of Wnt1 expression (Adams et al., 2000). The mesDA neurons of the mice 
homozygous null for Lmx1b have normal expression of their phenotypic and 
transcriptional markers and TH positive neurons are generated but they are lost during 
embryonic maturation (Smidt et al., 2000). Lmx1b is also required for the induction of 
Wnt1 expression in the chicken mid/hindbrain boundary region (Adams et al., 2000).  
 
 
 
       
 Engrailed (E9)           TH (E14)               En1 (E14) 
Figure-3: Pre-specification (E9) domain of expression of Engrailed and colocalization of Engrailed with 
TH in postmitotic (E14) neurons  (Simon et al., 2004). 
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2.2.4. Engrailed1/2 
 
The homeobox transcription factor, Engrailed, was first discovered in Drosophila 
melanogaster and has been extensively studied in this species (Eker, 1929). In 
drosophila, Engrailed has many major functions including development of a second 
sex comb, compartment and segment formation and wing development (Garcia-Bellido 
and Santamaria, 1972; Kornberg, 1981; Tokunaga, 1961). The cloning and sequencing 
of the mammalian (mouse) Engrailed has shown that it is highly conserved throughout 
evolution, with 75% homology to the drosophila Engrailed (Holland and Williams, 
1990; Joyner et al., 1985). In fact, the Drosophila Engrailed can substitute for mouse 
Engrailed-1 function 
in the mid-hindbrain 
development (Hanks 
et al., 1998). The two 
mammalian 
homologues, 
Engrailed-1 (En1) and 
Engrailed-2 (En2) 
both belong to the 
family of homeobox 
transcription factors 
and have about 95% 
sequence similarity in 
the, DNA binding, 
homeodomain 
(Davidson et al., 
1988). Genetically, 
En1 is located in the 
central portion of the 
mouse chromosome-1 
and En2 in the 
proximal portion of 
 
Figure-4: Gene dose dependency of mesDA neurons on the Engrailed 
genes and the functional redundancy of En1 and En2 (Simon et al., 
2001) 
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mouse chromosome-5 (Joyner and Martin, 1987). The replacement of En1 coding 
sequence with En2 sequence, by gene targeting, shows that the two genes are 
functionally redundant (Hanks et al., 1995). The two genes are expressed around E8 in 
the anterior neuroectoderm in two distinct nuclei but eventually the expression domain 
of both merge into the border region between midbrain and hindbrain (Simon et al., 
2004). During early embryogenesis, the Engrailed genes are involved in 
regionalization and also in specification of certain neuronal populations (Hidalgo, 
1998; Wurst and Bally-Cuif, 2001). The expression of both genes in the mesDA 
neurons starts between E11 and E12 and continues throughout the life of the organism 
(Simon et al., 2001). The post mitotic mesDA neurons require the Engrailed genes for 
their survival and maintenance in a gene-dose dependent manner. In the mice lacking 
both genes, the mesDA neurons differentiate, become post mitotic and start expressing 
TH but at the time of expression of the Engrailed genes in their wild type counterparts, 
around E12, they start to die and by E14 the entire population of mesDA neurons is 
lost (Simon et al., 2001). Mice homozygous null for En1, die at birth, while En2 
mutant mice only have a minor defect in cerebellar foliation (Millen et al., 1994; Wurst 
et al., 1994). With regard to the mesDA neurons, neither of the mutant mice, alone, 
shows major defects and both appear to be normal during embryonic development. 
Studies on mice, homozygous null for one gene and heterozygous for the other, show 
that the survival of mesDA neurons is dependent on the dose of Engrailed (Fig. 4). In 
the En1-/-En2+/- mice, the SNpc and VT are substantially diminished and the entire 
 
Figure-5: Postnatal, loss of DA neurons of En1+/-;En2-/- Mice. The loss happens after P15 and is 
limited to SN neurons and the number of mesDA neurons in VTA is unaltered (Sgadó et al., 2006). 
Introduction 
 
 
13 
DA population is reduced to a small cluster close to the ventral midbrain. The En1+/-
En2-/- mice appear to be normal during embryonic development but show a postnatal 
gradual loss of 70%, specific to the SNpc during the first three months of their lives 
(Fig. 5). The PD-like gradual loss of the nigral DA neurons is accompanied by 
diminished storage and release of dopamine in the caudate putamen, motor deficits 
similar to akinesia and bradykinesia, and a reduction in weight, all closely resembling 
the symptoms of PD. 
The initial studies on the mechanism of cell loss in the double mutant mice showed 
that the requirement for Engrailed is cell autonomous shown by cell mixing and RNAi 
experiments. The cultured mesDA neurons from the double mutant animals die in 72 
hours even when mixed with the dissociated ventral midbrain tissue from wild type 
animals, indicating that the pathway of death is triggered intrinsically and the survival 
requirement for Engrailed is independent of the surrounding tissue. Additionally, 
activation of caspase-3 and appearance of pyknotic nuclei, both markers of apoptotic 
cell death, have been seen in mesDA neurons in vitro and in vivo, suggesting apoptosis 
as the mechanism of cell death (Alberi et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
14 
3. Parkinson’s Disease, Pathology, Anatomy and Physiology 
of Dopamine System 
3.1. Clinical features of Parkinson’s Disease 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease, affecting approximately 1.5 to 2% of the population over the age 
of 55. The first set of clinical features include unilateral onset of resting tremor, 
muscular rigidity, and akinesia or bradykinesia which are the main clinical symptoms 
of PD, originally described by James Parkinson (Parkinson, 2002). In advanced stages, 
another set of problems appears, including dementia, depression, sleep disorders, 
sensory complaints, 
dysarthria, dysphagia, 
constipation and urinary 
dysfunction, masked 
facies, olfactory 
dysfunction, sialorrhea, 
seborrhea and orthostatic 
hypotension (Guze and 
Barrio, 1991; Hamani 
and Lozano, 2003). The 
first three of the 
symptoms are usually 
required and sufficient 
for diagnosis of PD and 
they become detectable 
when more than 50% of 
the mesDA neurons of 
the substantia nigra pars 
compacta (SNpc) are lost 
(Fearnley and Lees, 
1991; Steece-Collier et 
al., 2002). The cell loss 
 
 
Figure-6: The sites of neurodegeneration; Dopaminergic as well as 
other pathways of the brain, affected by PD (Lang et al., 1998).  
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during the early stages is specific to the SNpc and it is only in very late stages when, 
dopaminergic neurons of ventral tegmentum, the neighboring cell population, are 
affected (Damier et al., 1999). The second set of dysfunctions could be due to loss of 
other neuronal populations of the brain, including locus ceruleus, raphe nuclei, and 
nucleus basalis (Fig. 6) (Halliday et al., 1990a; Halliday et al., 1990b; Lang and 
Lozano, 1998a). While eventually the noradrenergic, serotonergic and cholinergic 
pathways are affected, cause of initiation and progression of PD is attributed to loss of 
the mesDA neurons and deficiency in dopamine level of the basal ganglia, the target 
tissue of nigral dopaminergic neurons.  
   
3.2. Dopamine Pathway, Pathophysiology of Parkinson’s 
Disease 
 
The mesDA neurons consist of the neurons located at three distinct nuclei, retrorubral 
field (RRF), substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA). 
DA neurons of VTA innervate into the ventromedial striatum, nucleus acumbens and 
the olfactory tubercle, forming the mesolimbic pathway, which is associated to 
pleasure, reward and desire (Oades and Halliday, 1987). Dysfunction in this pathway 
has been related to behavioral disorders, such as addiction and schizophrenia. The 
mesDA neurons of SNpc, on the other hand, exclusively innervate into the dorsal 
striatum, forming the nigrostriatal pathway, involved in motor control and implicated 
in Parkinson’s disease (Fig. 7). 
The prevailing model 
of pathophysiology 
of PD involves the 
structures in the basal 
ganglia and ventral 
midbrain, including 
regions of striatum 
(divided into three 
nuclei of putamen, 
caudate and nucleus 
 
Figure-7: Dopaminergic pathways arising from midbrain; the 
nigrostriatal and mesolimbic pathways in rat (adapted from 
http://www.chemistry.emory.edu/justice/). 
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accumbens), the external and internal segments of the globus pallidus, the subthalamic 
nucleus, and substantia nigra comprised of three nuclei of pars compacta, pars 
reticulata and pars lateralis. In this model, loss of SNpc neurons results in diminished 
release of DA to two striatal nuclei, caudate and putamen. Eventually, this results in 
increased inhibitory γ-aminobutyric acid (GABA)-ergic output from the basal ganglia 
via two pathways. The neurons, expressing dopamine receptor D1, directly project to 
the internal segment of the globus pallidus (iGP) and substantia nigra pars reticulata 
(SNpr), while the neurons expressing D2 receptor project to the external segment of 
the globus pallidus (eGP). The diminished release of dopamine to caudate and 
putamen is excitatory on the D1-expressing cells and it is inhibitory on the D2 
expressing cells. Therefore, the decrease in the DA level simultaneously causes a 
decrease in the GABAergic output to iGP and increased GABAergic output to eGP. 
The increased glutamatergic or decreased GABAergic input from the indirect or direct 
pathways, respectively, to the iGP and the SNpr results in increased thalamic 
inhibition, which leads to disruption of he activity of the cortical motor system, 
resulting in akinesia, rigidity and tremor (Fig. 8) (Albin et al., 1989; Lang and Lozano, 
1998b; Lindvall and Bjorklund, 1979; Olanow and Tatton, 1999). There has been no 
effective treatment against loss of nigral neurons and current PD drugs relieve the 
 
 
Figure-8: The basal ganglia model of pathophysiology of Parkinson’s disease. Loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) causes decreased level of DA in the striatum 
which, depending on the receptor, causes decrease or increase of the GABAergic output and via direct 
or indirect pathway, causes disruption of the cortical motor system. 
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symptoms by overcoming the effect of dopamine deficiency in the striatum instead of 
stopping the cell loss in SNpc. The dopamine agonists, like apomorphine, and the 
dopamine precursor, L-DOPA serve such a purpose. The monoamine oxidase-B 
(MAO-B) inhibitors like Selegiline and Rasagiline also compensate for dopamine 
deficiency by inhibiting breakdown of secreted dopamine (Youdim et al., 2005). 
  
3.3. Biochemistry and Molecular Biology of Dopamine Pathway 
 
A neurotransmitter for slow synaptic transmission, dopamine (4-(2-
aminoethyl)benzene-1,2-diol) is a member of the catecholamine family of 
neurotransmitters, which are synthesized from tyrosine. The steps in dopamine 
synthesis include hydration of tyrosine to L-DOPA (3,4-dihydroxy-L-phenylalanine) 
by tyrosine hydroxylase (TH) and decarboxylation of L-DOPA to dopamine by 
aromatic-L-amino acid 
decarboxylase (AADC). 
The rate-limiting enzyme of 
this process, TH, is often 
used to identify 
dopaminergic neurons. 
After synthesis, DA is 
packed into vesicles and 
released into the synaptic 
cleft, which binds to DA 
receptors in postsynaptic 
terminal. The unbound DA 
is taken up by DA 
transporter (DAT) and after 
reuptake, the DA inside the 
cell is either degraded to 
DOPAC by monoamine 
amine oxidase type B 
(MAO-B) or recycled into  
 
Figure-9: Synthesis, release, uptake, degradation and receptor 
binding of dopamine . 
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vesicles (Fig. 9).  
The binding of DA to its receptors can cause inhibition or excitation, depending on 
type of the receptor. The dopamine receptors comprise 7-transmembrane domain and 
are metabotropic G protein coupled receptors, consisting of five members, D1-D5.  
The D1-like receptors, D1 and D5, are excitatory and induce their function by 
increasing the intracellular level of cyclic-AMP (cAMP) via adenylyl cylcase and 
subsequently, the level of cAMP-dependent protein kinase-A (PKA) The D2 like 
receptors, D2, D3 and D4, have inhibitory function with their activation resulting in 
reduction of cAMP levels. One important pathway of D1 signaling includes 
phosphorylation of DARPP32 by PKA which causes enhanced NMDA response 
(Girault and Greengard, 2004; Greengard, 2001a; Greengard, 2001b).  
 
3.4. Experimental Models of Parkinson’s Disease 
 
The most common method to simulate the events of basal ganglia is to induce death of 
nigral DA neurons by specific neurotoxins. The widely used substances for this 
purpose are 6-OHDA and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
which induce specific loss of nigral neurons or agricultural toxins like rotenone and 
maneb. 6-OHDA is a hydroxylated analogue of DA which can cause catecholamine 
depletion in the brain after application into the basal ganglia or lateral ventricles 
(Ungerstedt, 1968). The mode of action of 6-OHDA is via production of reactive 
oxygen species (ROS). Generation of hydrogen peroxide and hydroxyl radicals and 
auto-oxidation by involvement of monoamine oxidase (MAO), iron, and Fenton 
reaction are some of the chemical events, causing oxidative stress (Blum et al., 2001). 
6-OHDA also induces mitochondrial dysfunction by direct inhibition of complex-I of 
the mitochondrial respiratory chain in cell-free environments (Glinka and Youdim, 
1995). This effect is reversible and independent of ROS and could not be replicated in 
the whole cell experiments, suggesting that inhibition of complex-I is not causal to 
production of ROS (Blum et al., 2001). However, the mitochondrial membrane 
damage occurs upon application of 6-OHDA, where ROS is likely to be responsible 
for the impairment of the mitochondrial membrane (Lotharius et al., 1999). 
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An analogue of the narcotic meperieine, MPTP, was first discovered in heroin addicts 
who displayed clinical characteristics of Parkinson’s disease (Langston et al., 1983) 
and has been widely used, ever since, on different species to model nigral cell loss and 
PD symptoms. MPTP passes the blood brain barrier and is transformed (by MAO) to 
its active form, MPP+, which can be taken up by DAT and accumulated inside 
dopaminergic cells. The cytosolic MPP+ can enter mitochondria and inhibit complex-I, 
which in turn leads to inhibition of oxidation of NAD+ linked substrates (Mizuno et 
al., 1989). The mitochondrial events lead to decreased ATP levels inside the cell, loss 
of mitochondrial membrane potential, alteration of calcium homeostasis, and free 
radical formation. The inhibition of complex-I is only partially responsible for 
production of ROS, since mitochondria deprived Rho0 cells also respond to MPP+ 
(Przedborski and Jackson-Lewis, 1998). Similar to 6-OHDA, MPTP also causes an 
increase in iron levels in nigral neurons, resulting in added oxidative stress (Blum et 
al., 2001; Przedborski and Jackson-Lewis, 1998). In both, 6-OHDA and MPTP 
models, the mitochondrial impairment has been linked to the classical pathways of 
apoptosis, especially the mitochondrial pathway (Vila and Przedborski, 2003b).  
 
4. Apoptosis and Parkinson’s Disease 
4.1. Extrinsic and Intrinsic Pathways of Apoptosis 
 
The term apoptosis, as it is known today, was first used in 1972 by Kerr et al. (Kerr et 
al., 1972) to describe a novel form of dying which differed in many ways from other 
modes of programmed cell death. Since then, it has become the main focus of research 
concerning normal developmental cell death and also too little or too much unwanted 
cell loss in disorders ranging from cancer to neurodegenerative diseases. The 
morphological characteristics of apoptosis include cell shrinkage, chromatin 
degradation and condensation, membrane blebbing and nuclear fragmentation (Kerr et 
al., 1972). Traditionally, apoptosis has been classified into caspase-dependent or 
independent mechanisms and, based on the mode of initiation, arbitrated via two major 
interconnected pathways, the death receptor-mediated, or extrinsic, and the 
mitochondrial or intrinsic cascades. 
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4.1.1. Receptor Mediated/ Extrinsic Pathway 
 
The extrinsic pathway of apoptosis is activated upon interaction of the tumor necrosis 
family (TNF) members with the cysteine-rich, extracellular sub-domain of their 
respective death receptors, which belong to the TNF receptor (TNFR) gene family. 
The eight-member family of receptors includes CD95 (Fas or APO-1) and TNFR1 
(p55 or CD12a). The ligand-receptor interaction leads to recruitment of the adaptor 
molecules and formation of signaling complexes and activation of caspase-8 and 
caspase-3. For example, in the case of CD95, the interaction of the Fas ligand with its 
receptor leads to recruiting of the adapter molecule, Fas associated death domain 
(FADD), and procaspase-8. Association of the death domains of the Fas receptor and 
FADD plus interaction of the death effector domains (DED) of FADD and procaspase-
8 from one side and FADD with the Flice inhibitory protein (FLIP) from the other side 
(CD95L&R, FADD, procaspase-8 and FLICE make up DISC), lead to cleavage of 
caspase-8 and subsequent activation of an apoptotic cascade, plus instigation of an 
inherent inhibitory mechanism opposing the initiation of this deleterious process 
(Smith et al., 1994) (Ashkenazi and Dixit, 1998) (Peter and Krammer, 2003) (Lavrik et 
al., 2005). Activation of caspase-8 leads to activation of the effector caspases like 
caspase-3, 6 or 7 (Fig. 10). The TNFR1 apoptotic signaling pathway employs a similar 
mechanism of receptor-ligand interaction, formation of death signaling complex and 
activation of caspase-8 and subsequently, activation of the executioner caspases. This 
mechanism could directly lead to destruction of the cell or to activation of the, 
otherwise independent, machinery of mitochondrial pathway. 
 
4.1.2. Mitochondrial/ Intrinsic Pathway 
 
Although mitochondrial apoptosis could be considered a magnifying step for caspase 
activation and other pathways of apoptosis, intrinsic stimuli such as reactive oxygen 
species cause mitochondrial dysfunction and, eventually, lead to apoptosis. A crucial 
event in this process is the release of cytochrome C and other pro-apoptotic molecules 
(like AIF and SMAC/Diablo) from the mitochondrial outer membrane. About 90% of 
cytochrome C is stored in vesicles formed from mitochondrial inner membrane and 
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10% is located at the intermembrane space (Mayer and Oberbauer, 2003).  
Cytochrome C has a defined role as being an electron transfer protein in mitochondrial 
oxidative phosphorylation. The apoptotic role of cytochrome-C involves its release 
into the cytosol and being an essential component in formation of apoptosome, the 
structure required for activation of caspase-9. Although the exact mechanism of the 
cytochrome C release into the cytosol is not known, there are several hypotheses about 
the structural changes in mitochondrial membrane permeability, due to interplay of 
several molecules and mechanisms, with the members of the Bcl-2 family acting as the 
main regulators of the overall process. The changes in the membrane permeability are 
associated with formation of the mitochondrial permeability transition pore and other 
membrane channels, involving the members of the Bcl-2 family and the upstream 
regulatory proteins, such as p53 (Polster and Fiskum, 2004).  
The multipeptide channel, mitochondrial permeability transition (MPT) pore forms at 
the contact site of the two membranes, consisting of peptides like voltage dependent 
anion channel (VADC) on the outer membrane and adenine nucleotide translocator 
(ANT) on the inner membrane plus other molecules from the matrix and 
intermembrane space (Zoratti and Szabo, 1995). Bax, a pro-apoptotic member of the 
Bcl-2 family, interacts with individual components of the mitochondrial permeability 
transition pore (Adachi et al., 2004; Shimizu et al., 1999). Binding of the anti-
apoptotic members of this family can close the VDAC and inhibit apoptosis (Shimizu 
et al., 2000). Despite these interactions, the permeability transition pores can cause 
apoptosis on their own and the Bcl-2 family members can regulate release of 
cytochrome C independent of these pores. Therefore, the interaction of members of the 
Bcl-2 family with VDAC, ANT and other components of the MPT pore is only one of 
the ways these proteins induce their pro and anti apoptotic functions. 
 
4.1.3. Bcl-2 Family Members 
 
Members of the Bcl-2 family are classified into three groups of pro-apoptotic, anti-
apoptotic and BH3-only, sharing at least one conserved Bcl-2 homology (BH) domains 
(Borner et al., 1994). Each of the BH domains is involved in a specific function. The 
BH3 domain is responsible for progression of apoptosis while BH4 domain induces 
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anti-apoptotic activity. BH1 and BH2 are used in formation of the structures necessary 
for interaction and oligomerizatin of the members of this family. Therefore, the anti-
apoptotic members, including Bcl-2, Bcl-XL, Bcl-w and Mcl-1 have all four domains 
where BH4 domain is missing from the pro-apoptotic members like Bax and Bak. 
Other members like Bid, Bok, Bim and Bad only have the BH3 domain (Huang and 
Strasser, 2000).  
Beside the interactions with mitochondrial transition permeability pore, the pro-
apoptotic members of the Bcl-2 family, can also form new channels and induce 
membrane lipid alterations (Sharpe et al., 2004). In non-apoptotic cells, Bax exists as 
an inactive monomer either in the cytosol or loosely bound to the mitochondrial outer 
membrane. Upon activation by apoptotic stimuli, including interaction with truncated 
Bid (t-Bid), Bax undergoes a conformational change, which allows the disengagement 
of its C-terminal anchor domain from the hydrophobic groove and insertion into the 
mitochondrial outer membrane (Nechushtan et al., 2001). Insertion into the membrane 
is followed by Bax oligomerization, which requires further conformational change and 
release of the BH3 domain, required for Bax-Bax homodimerization or 
heterodimerization of Bax with pro-survival members of the family (Chan and Yu, 
2004). 
Studies on the structure of the Bcl-XL show that the BH-1 and BH-2 domains, along 
with the BH3 domain, form a hydrophobic groove on the surface of the anti-apoptotic 
members of the Bcl-2 family to which the alpha helical BH3 domain binds (Muchmore 
et al., 1996) (Sattler et al., 1997). The exact molecular mechanism of protection by the 
pro-survival members of the Bcl-2 family is not known but dimerization with their 
pro-apoptotic relatives (by interaction of the amphipathic alpha-helical BH3 domain of 
one member with the hydrophobic surface groove of another) is essential to their 
function. Therefore, the ratio of pro apoptotic to the anti apoptotic members is 
essential in regulation of mitochondrial sensitization and the rate of death via the 
intrinsic pathway. Likewise, the BH3-only proteins can induce apoptosis by direct 
interaction with the pro-apoptotic members (synergistic and activating effects) or 
neutralizing the effect of anti-apoptotic members (inhibition of heterodimerization 
with pro-apoptotic members).  
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4.1.4. Downstream of the Mitochondria 
 
After the release of cytochrome C from the mitochondrial intermembrane space into 
the cytoplasm, it binds to and oligomerizes the apoptotic protease activator factor 1 
(Apaf-1) and procaspase-9 to form the apoptosome (Li et al., 1997). The main mode of 
activation of caspase-9 is through conformational changes of procaspase-9 via 
association with the other two molecules (Rodriguez and Lazebnik, 1999). Formation 
of the activating protein complexes (apoptosome for caspase-9 and DISC for caspase-
8) is a common molecular event in activation of initiator caspases, while the effector 
caspases are activated through proteolytic cleavage by their respective initiator 
caspases (Shi, 2004). In the same way, activation of caspase-9 mainly leads to 
activation of caspase-3, which is also the effector caspase of the death receptor 
mediated apoptosis. 
Beside the caspase-dependent pathways, mitochondria could be involved in several 
other apoptotic processes including release of the apoptosis inducing factor (AIF) and 
activation of the caspase-independent pathway (Joza et al., 2001). The mitochondrial 
pathway is considered as a magnifying step for the extrinsic apoptosis in certain cell 
types with low levels of activation of caspase-8 (Scaffidi et al., 1998).  In such cells, 
the Bcl-2 family member, Bid, is truncated by caspase-8 and the truncated Bid (tBid) 
will mediate release of cytochrome C and activation of caspases 9 and 3 (Li et al., 
1998; Luo et al., 1998). The activation of caspase-3, downstream of caspase-8 and/or 
caspase-9 (Stennicke et al., 1998), leads to cell death due to its cleavage and, therefore, 
degradation and inactivation of proteins (like the caspase activated DNAse, CAD, or 
Bcl-2 proteins) and destruction of cellular structures (like lamin) (Thornberry and 
Lazebnik, 1998). 
 
4.2. PD and Apoptosis 
 
Although the causes of vulnerability and degeneration of the mesDA neurons are still 
unknown, the evidence like involvement of the death receptors and their ligands, 
mitochondrial dysfunction and increase in activation of caspases suggest the extrinsic 
and intrinsic pathways of apoptosis as the executioners of neuronal cell death 
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(Hartmann and Hirsch, 2001; Hartmann et al., 2000; Tatton et al., 2003; Vila and 
Przedborski, 2003b). Mitochondria is the site of action for several deleterious 
processes involved in pathogenesis of PD. Reduced activity of mitochondrial complex-
I and production of reactive oxygen species are found in postmortem brains of PD 
patients and can cause specific loss of mesDA neurons of SNpc in the three major 
neurotoxin-based models of the disease, MPTP, Rotenone and 6-OHDA (Schapira et 
al., 1990; Schober, 2004). Additionally, the inhibition of complex-I results in 
permeability of the mitochondrial membrane and release of pro-apoptotic molecules, 
including cytochrome C, into the cytoplasm and subsequent activation of caspases, 
leading to apoptotic cell death (Kroemer et al., 1998; Perier et al., 2005). In animal 
models of PD, this effect could be ablated by high expression of Bcl-2 and Bcl-XL the 
anti-apoptotic members, or genetic ablation of Bax, the pro-apoptotic member of the 
Bcl-2 family (Vila et al., 2001; Yang et al., 1998). 
 
4.2.1. The Death Receptor Mediated Pathway and PD 
 
Human postmortem studies implicate the involvement of death receptor induced cell 
death in PD. The levels of pro-inflammatory cytokines like TNF-α are elevated in the 
brain and cerebrospinal fluid of PD patients (Mogi et al., 1994) and the density of TNF 
positive glial cells in SNpc of PD patients is higher than the healthy individuals (Boka 
et al., 1994). The human studies also suggest an increase in the soluble form of 
Fas/CD95 in PD patients (Mogi et al., 1996). Furthermore, the expression of Fas 
associated death domain (FADD), in dopaminergic neurons is limited to mesDA 
neurons and especially to the SNpc (Hartmann et al., 2002a). Despite these 
observations, the data from the neurotoxin based animal models is controversial. For 
instance, the studies from CD95 knockout mice assume both, neuroprotective and 
apoptotic roles for this ligand-receptor pathway (Hayley et al., 2004; Landau et al., 
2005). Similarly, results of the studies about the role of TNF receptors have been are 
contradicting and both in favor or against their involvement in loss of mesDA after 
neurotoxin treatment (Rousselet et al., 2002; Sriram et al., 2002).  
Introduction 
 
 
25 
4.2.2. The Mitochondrial Pathway and PD 
 
Mitochondria are the site of convergence of many deleterious processes.  Some of the 
mitochondrial events, supporting the notion of involvement of the intrinsic pathway of 
apoptosis in PD, observed in postmortem brains of PD patients and most (if not all) of 
the animal and cellular models of this disease, are activation of the effector and 
initiator caspases of the mitochondrial apoptosis, caspase-3 and caspase-9, release of 
 
 
Figure-10: Extrinsic and Mitochondrial pathways of apoptosis, neurotoxin induced vulnerability of 
mitochondria  and the anti-apoptotic role of neurotrophins. 
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cytochrome C and AIF from mitochondria to the cytosol, differential expression and 
regulation of members of the Bcl-2 family, alterations in the activity of complex-I of 
the electron transport chain and excessive production of the reactive oxygen species 
(ROS). Therefore, mitochondrial dysfunction is considered a decisive point in etiology 
of PD. 
The activity of the mitochondrial complex-I (NADH/ubiquinone oxidoreductase) is 
reduced specifically in the substantia nigra of the PD patients (Schapira et al., 1990). 
This biochemical defect is also present in three major neurotoxin induced models of 
PD, MPTP, 6-OHDA and Rotenone (Schober, 2004). In addition to causing oxidative 
damage to DNA, proteins and membrane lipids, (similar to the effect of excessive 
Ca2+) excessive production of ROS by inhibition of complex-I, can trigger release of 
the pro-apoptotic proteins from mitochondria by interacting with classical 
mitochondrial apoptosis (Fiskum et al., 2003). This interaction has been demonstrated 
in the mouse MPTP model where complex I deficiency, caused by chronic application 
of MPTP, increases the level of cytochrome C in the mitochondrial intermembrane 
space and triggers mitochondrial localization of Bax (Perier et al., 2005). 
In postmortem brains of PD patients, expression of the BCl-2 family members is 
affected by the disease. Bax is expressed and present in higher percentages in the 
Lewy body containing (PD suffering) neurons than other mesDA neurons of the same 
subjects (Hartmann et al., 2001). Also, the expression of Bcl-XL is doubled in the 
mesDA neurons of PD patients (Hartmann et al., 2002b). The role of the members of 
this family, also, has been demonstrated in the animal models. The neurons from 
transgenic mice, over-expressing human Bcl-2, are resistant to neurotoxicity, induced 
by 6-OHDA and MPTP (Offen et al., 1998; Yang et al., 1998) while Bax ablation can 
have similar results in MPTP treated animals (Vila et al., 2001). In a genetic model of 
PD, where alpha-synuclein has a dual function, Bcl-2, Bax and Bcl-XL contribute to 
survival as well as death (Seo et al., 2002). A comprehensive picture about different 
functions of the Bcl-2 family members is yet to emerge, since in addition to regulation 
of the oxidative stress (Hochman et al., 1998), members of the Bcl-2 family are 
considered to be involved in the general survival and maintenance of the mesDA 
neurons (Savitt et al., 2005), further associating the pivotal role of mitochondrial 
apoptosis to the vulnerability of this neuronal population. 
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The events downstream of the mitochondria, like release of cytochrome C, 
Smac/DIABLO or AIF, have not been studied in human tissue and the activation and 
expression of caspase-3 is the only event that happens in the SNpc of PD patients 
(Hartmann et al., 2000). On the other hand, in the animal models of PD, there is 
growing evidence suggesting the activation of caspase-dependent and independent 
pathways, downstream of the mitochondria. In these models, activation of caspases 
arbitrates the death signal from the mitochondria or other upstream pathways, like P53 
or the death-mediating MAPK pathways, P38 and c-Jun N-terminal kinase (JNK) 
(Blum et al., 1997; Choi et al., 2004; Lotharius et al., 2005; Wang et al., 2004). 
 
5. Trophic Factors in Survival of MesDA Neurons 
 
Neurotrophic factors regulate many essential processes including neuronal survival, 
death and plasticity in the CNS. Three major families of neurotrophic factors are the 
neurokines, including the cilliary neurotrophic factor (CNTF), glial derived 
neurotrophic factor (GDNF) family and the nerve growth factor (NGF) related 
neurotrophins. GDNF and the brain derived neurotrophic factor (BDNF), belonging to 
the two latter super-families, are the most effective survival factors for mesDA 
neurons during the course of development or in preventing neurotoxin-induced cell 
loss in animal models of PD (Henderson et al., 1994; Hyman et al., 1991; Spina et al., 
1992; Tomac et al., 1995). 
 
5.1. Glial Derived Neurotrophic Factor 
 
A member of the transforming growth factor-ß (TGF- ß) super family, GDNF is a 
general anti-apoptotic and survival factor for mesDA neurons in vivo and in vitro 
(Clarkson et al., 1997; Tomac et al., 1995). Unlike other TGF-ß family members where 
the signaling happens through the receptor serine-tyrosine kinases, the neurotrophic 
function of GDNF family ligands (GFL’s) is activated when these ligands bind to their 
cognate GDNF-family receptor-α (GFRα), resulting in activation of the Ret 
(rearranged during transformation) tyrosine kinase (Airaksinen and Saarma, 2002). 
The high affinity binding of GFLs to one of the GFRα receptors dimerizes Ret, 
Introduction 
 
 
28 
resulting in phosphorylation of tyrosine domains on the Ret molecules which become 
the binding sites for Src homology-2 SH2 domain of the interacting intracellular 
signaling molecules(Cacalano et al., 1998). The intracellular pathways, activated 
through this mechanism include phosphatidylinositol 3 kinase (PI3K), the mitogen 
activated protein kinase (MAPK) pathway inducing processes like proliferation, 
differentiation, migration, neurite outgrowth and survival (Airaksinen and Saarma, 
2002; Koeberle and Ball, 2002; Neff et al., 2002; Saarma and Sariola, 1999). In 
mesDA neurons, GDNF induces its anti-apoptotic function through mechanisms such 
as, over-expression of Bcl-2 and Bcl-XL(Sawada et al., 2000),  enhancement of TH 
phosphorylation(Kobori et al., 2004) and activation of Erk1/2 and PI3K pathways 
(Ugarte et al., 2003). 
 
5.2. Neurotrophins and Their Receptors 
5.2.1. Neurotrophin Receptors 
 
Neurotrophins, consisting of BDNF, NGF, NT3 and NT4/5, induces their action via a 
set of specific tyrosine kinase receptors (Trk) and a common receptor (P75). The 
induction of the kinase activity of the (Trk) tyrosine receptor kinase family members, 
TrkA, TrkB and TrkC, by their respective neurotrophins, NGF, BDNF or NT4/5 and 
NT3 is mainly pro-survival. This survival function is through homodimerization of the 
Trk receptors upon binding of neurotrophins and trnasphosphorylation of tyrosine 
residues in their cytoplasmic domains which (similar to Ret) become the site of 
interaction with the Src homology domain-containing adaptor protein (SHC) which, 
via recruitment of other specific adaptor proteins, causes involvement of the Ras 
pathway, resulting in activation of PI3K and MAPK/Erk1/2 (Atwal et al., 2000; Liu 
and Meakin, 2002; Obermeier et al., 1993)(Fig. 11). A similar mechanism has been 
envisioned for P75-Trk regulated survival while the exact underlying mechanism is not 
known yet. 
The dual (pro-survival or pro-apoptotic) function of P75 neurotrophin receptor 
depends on the neurotrophins, its dimerizing partner and the factors binding to its 
intracellular death domain (Fig. 11). While the type of neurotrophins could be a factor 
in deciding the function of P75, it is form of the ligand, i.e. the pro or mature form, 
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that is the key to determining the apoptotic or survival mediating function of p75 (Lee 
et al., 2001).  Neurotrophins in their pro form have a high affinity for p75 than Trk 
receptors and upon binding, force p75 to dimerize with Sortilin while the mature 
neurotrophins have a high affinity for Trk receptors and cause homodimerization of 
them or their heterodimerization with P75 (Nykjaer et al., 2004). On the other hand, 
the mere over-expression of P75 can result in apoptosis, mediated by phosphorylation 
of JNK and BH3-only members of the Bcl-2 family (Fig. 11) (Bhakar et al., 2003). 
The binding of intracellular proteins, like NRAGE to the death domain of P75 can also 
induce cell death via activation of MAPK’s and mitochondrial dysfunction(Salehi et 
al., 2002). In this paradigm the survival mediating role of Trk’s can be viewed as 
inhibition of the death machinery of P75 with the decision of life and death being 
made by activation of the signaling pathway of MAPK’s, Erk1/2 and JNK, 
respectively. 
  
5.2.2. Neurotrophins 
 
While there has been some evidence for NGF protective role against MPP+ treatment 
in PC12 cells, (Shimoke and Chiba, 2001) there is not much evidence for NGF as a 
survival factor for mesDA neurons, probably due to the lack of expression of its 
cognate receptor, TrkA in these neurons (Melchior et al., 2003). Among neurotrophins, 
the survival effect of BDNF in mesDA neurons and its protective role against 
neurotoxin-induced cell death is the most pronounced (Hyman et al., 1991). Reduced 
level of BDNF in nigral mesDA neurons and their surrounding tissue in PD patients 
(Howells et al., 2000) may provide a link between lack of BDNF and the human 
condition. Additionally, observations from gain and loss of function experiments in the 
animal models support the notion of BDNF as a potent survival factor for mesDA 
neurons. While the mRNA level of BDNF decreases upon application of neurotoxins, 
(Venero et al., 1994), application of BDNF protects cells from toxicity induced by 6-
OHDA and MPTP (Frim et al., 1994; Shults et al., 1995). On the other hand, BDNF 
knockdown by antisense oligonucleotides or conditional knock out causes loss of 
mesDA neurons (Baquet et al., 2005; Porritt et al., 2005).  
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Other members 
of the 
neurotrophin 
family have a 
lesser, yet 
significant, effect 
on mesDA 
neurons. Because 
of binding to the 
same Trk 
receptor (TrkB), 
the function of 
NT4 is very 
similar to that of 
BDNF to the 
degree that it can 
rescue the BDNF 
deficient mice 
when knocked 
into the BDNF 
locus (Fan et al., 2000). In mesDA neurons, NT4, is protective against toxic effects of 
iron and nitric oxide(Lingor et al., 2000). It is also beneficial to nigral explant cultures, 
when combined with GDNF (Altar et al., 1994). Furthermore, NT4 could be involved 
in locomotor control since in the D2 receptor-deficient mice, which display motor 
dysfunction, its mRNA level is lower (Bozzi and Borrelli, 1999). NT3 has a lesser, yet 
significant effect (in comparison to BDNF and NT4) as a survival factor for mesDA 
neurons and in eliminating the behavioral deficits caused by partial 6-OHDA lesions 
(Altar et al., 1994). 
 
 
 
 
 
Figure-11: The molecular pathway of neurotrophins, their receptors 
and downstream pathways. Mere overexpression of P75 or its binding 
to sortilin induces apoptosis via JNK or P38, as opposed to the pro-
survival role of the Trk receptors which are pro-survival and activate 
the Etrk1/2 pathway. 
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5.3. Downstream Effectors of Neurotrophins 
 
The pro-survival role of GDNF, BDNF and other neurotrophins has been attributed to 
activation of two downstream pathways, the phosphotydil inositol-3 kinase (PI3K) and 
the extracellular receptor kinase 1/2(Erk1/2) (Krieglstein et al., 2002). PI3K is mainly 
considered a survival pathway, being activated by many factors including expression 
of α-synuclein, presence of GDNF, BDNF, and other neurotrophins (Salinas et al., 
2003; Seo et al., 2002; Ugarte et al., 2003). 
Mitogen activated protein kinases (MAPKs) consist of three distinct molecular 
pathways with opposing functions. While JNK and P38 are classically known as stress 
induced pathways, triggering apoptosis, Erk1/2 pathway is generally considered pro-
survival and a mediator of action of neurotrophins (Xia et al., 1995). Mechanism of 
activation of Erk, like the other two MAPK, is dependent upon its upstream G-protein, 
MAPKKK, and MAPKK activities. Therefore, a mechanism consisting of Ras, Raf 
and MEK is responsible for activation of Erk. Activation of the proto-oncogene, Ras, 
is dependent upon GDP-GTP exchange (McCormick, 1993). The activation of Ras can 
result in activation of all three types of mammalian Raf, Raf-1, A-Raf and B-Raf 
(Kolch, 2000). Mek1/2 is an activation target for all three homologues of Raf, which, 
in turn, phosphorylates a motif of Thr-Glu-Tyr in the activation loop of Erk1/2 (Kolch, 
2000). Erk1/2 has also been considered independent of its upstream MAPKK molecule 
(MEK) and, for example, P75 can directly interact with Erk1/2, upon addition of NGF 
(Volente et al., 1993). While the kinase activity of the Trk receptors, via its 
intracellular domain, clearly signals survival, the exact molecular mechanism and 
outcome of P75-Trk interaction with regard to activation of the downstream pro-
survival or pro-apoptosis MAPKs is not well understood. 
Contrary to the traditional view about the role of Erk1/2, there is also evidence, 
suggesting a pro-apoptotic function for Erk1/2. This function depends on the site and 
duration of activation and has been observed only in vitro. While sustained, 
cytoplasmic activation of Erk1/2 is consistent with its pro-survival role, its short term, 
nuclear activation seems to cause apoptosis via a caspase-independent mechanism 
(Oh-hashi et al., 1999; Subramaniam et al., 2004; Torii et al., 2004; Troadec et al., 
2002). In mesDA neurons, Erk1/2 is involved in many processes including regulation 
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of trophic factor survival and neurotransmitter synthesis. With regard to neurotrophic 
factors and mesDA neurons, Erk1/2 is known as one of the downstream effector of 
GDNF signaling (Nicole et al., 2001; Ugarte et al., 2003). Erk1/2 is also important to 
the neurotransmitter synthesis in mesDA neurons. The activation of tyrosine 
hydroxylase is a result of its phosphorylation at three distinct sites (ser-19, 31, 40) of 
which, two, ser-31 and ser-40, are responsible for synthesis of dopamine and 
regulation of these two sites has been linked to activation of Erk1/2 and protein kinase 
A (Haycock et al., 1992; Kobori et al., 2004).  
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1. Generation of the Mice and Genotyping 
1.1. Generation and Maintenance of the Mice 
 
The En1/tau-lacZ mice were generated by a knock in strategy, where the first 71 
codons of the En1 gene, including the first codon, including the start codon, were 
replaced by the Tau-lacZ (Callahan and Thomas, 1994) sequence, as described in 
(Saueressig et al., 1999). Generation of the En2-deficient mice, done by targeted gene 
deletion, has been described in (Joyner et al., 1991). The two lines were crossed for 
obtaining EnDM, EnHT and En2-/- animals. 
 
1.2. Extraction of Genomic DNA 
 
About 1cm tail biopsy from 4-6 weeks old mice were collected and stored at -20°C. 
For digestion of the tails, each tail was incubated overnight at 55°C in 550ul TNES 
buffer (50 mM Tris, 0.4 M NaCl, 100 mM EDTA, and 0.5 % SDS) with 350ug of 
proteinase-K (Applichem, Germany). After digestion, 180ul 5M NaCl was added to 
the samples following by a 15min. centrifugation at 14000rpm. The supernatant was 
transferred to a new tube. An equal volume of 96% ethanol (750ul) was added to the 
supernatant and centrifuged at 14000rpm for 30min. The supernatant was drained and 
the pellet was air-dried. The pellet was dissolved in 300ul H2O or TE (10mM Tris 
pH=8, 1mM EDTA) and stored at 4°C for PCR.  
 
1.3. Genotyping  
 
For producing three genotypes of En1 i.e. wild type, heterozygous and mutant, all in 
En2-/- background, crossing was made using parents with En1+/- En-/- genotype. The 
genotyping for En2 wild type and mutant alleles was performed by PCR using the 
following three primers in the same mix, the common primer, 
TTGAGAAGAGAGGCCCTGTA, the wild type primer, specific for En2 homeobox, 
CTGGAACAAAAGGCCAGTGT, and the, TCTCATGCTGGAGTTCTTCG in the 
neomycin gene, to detect the En2 mutated allele/s. The primers for detecting the 
knocked in Tau-LacZ allele were GTGTCCGGCAGCTTGGTCTT on the Tau-LacZ 
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gene, and TTCGCTGAGGCTTCGCTTTG, starting at position 224 of the exon-1 of 
En1. The PCR settings for En were 5 min at 94°C, 36 cycles (45 sec at 94°C, 1min at 
54°C, 1 min at 72°C), 5 min at 72°C and for En1 they were 4 min at 94°C, 30 cycles 
(45 sec at 94°C, 1min at 54°C, 1 min at 72°C), 4 min at 72°C. The PCR mix consisted 
of 2.5 mM MgCl2, 10x buffer, 1mM dNTP and 2% primer mix and 1% Taq 
polymerase (all from Fermentas, Germany) plus 1µg/µl DNA (2% of the total 
volume). Alternatively, for detection of the tau-lacZ, X-gal staining was used by 
incubating the toes of embryos/animals in  the solution, containing 5 mM K3Fe(CN)6 
(Sigma, Germany), 5 mM K4Fe(CN)6⋅3H2O (Sigma, Germany), 2 mM MgCl2 and 
with 1mg/ml X-Gal (AppliChemGmbH, Germany) for 30min at 37ºC. 
 
2. Primary Culture of Ventral Midbrain 
2.1. Preparation of Laminin-Coated Cover slips 
 
12mm glass cover slips (NeoLab, Germany) were boiled in 80% ethanol and sterilized 
by rinsing in 100% ethanol and flaming. Alternatively, cover slips were placed in front 
of the ultraviolet lamp overnight. Then, they were placed into the 24 well culture 
dishes and covered with 500µl polyornithin solution (polyornithin 0.1 mg/ml (Sigma) 
in 15mM borate buffer (Sigma, Germany) pH 8,4.) for (at least) one hour at room 
temperature. The cover slips were washed for three times successively with sterile 
water. 1mg/ml aliquots of laminin (Sigma, Germany) were thawed slowly on ice and 
dissolved (1:1000) in DMEM-F12 (Invitrogen, Germany). The cover slips were 
covered by 500µl Laminin dissolved in DMEM (final concentration: 1µg/ml) and 
incubated at 37° from 2 hours to overnight. Right before culturing, the cover slips were 
washed (once) and covered by DMEM-F12 to avoid drying. 
 
2.2. Dissection, Dissociation and Culturing of Ventral Midbrain 
 
The embryos were collected in the L15 (Leibovitz) medium (Cambrex, Belgium). 
Ventral mesencephalon from E12 WT, HZ, En2-/- and MT embryos were dissected 
using scissors and forceps. The meningis were removed and the extra pieces were cut 
using a sterilized blade. The dissected ventral midbrain pieces were put into the L15 
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medium on ice for up to 45min. The L15 medium was aspirated and 0.5ml 0.25% 
trypsine-EDTA (Invitrogen/Gibco, Germany) was added following by 15min. 
incubation at 37°C. The 0.25% trypsine-EDTA was removed and 0.5ml L15 plus 
0.5ml fetal calf serum (FCS) (Invitrogen, Germany) was added. The combination of 
L15 and FCS was removed and the pieces of tissue were washed twice with 1 ml 
complete medium containing DMEM-F12 with 1% glutamine (Invitrogen, Germany), 
1% Penicillin/Streptomycin (final concentration: 50U/mlPen. -50µg/ml Strep.) 
(Invitrogen, Germany), 0.36% (or 33mM) glucose (Sigma, Germany), 0.25% BSA 
(Sigma, Germany), 1% N2 medium (Invitrogen, Germany) and 5% FCS. After the 
washes, the cells were dissociated using gentle triturating with a flamed Pasteur pipette 
(with restricted tip). The tubes were centrifuged at 1000g for 10min. in an 
ultracentrifuge (Beckmann TL, rotor TLS 55). The medium was removed and replaced 
with 500µl fresh complete medium. The number of cells was adjusted to 150000 per 
cover slip and the cells were plated on polyornithin/laminin pre-coated cover slips. 
After one hour at 37°C, when the cells were attached, the cover slips were placed into 
24 well culture dishes with 500µl complete medium. 500µl medium was added after 
24 hours and the cells would survive for up to 30 days. For treatment with neurotoxins, 
transfection with siRNA or with the inhibitory substances, serum free medium was 
used, containing the complete medium without the FCS.  
 
3. Cell lines 
 
Cells were maintained at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s 
medium/F-12 (Invitrogen, Germany) 100units/ml penicillin, and 100 µg/ml 
streptomycin (Invitrogen, Germany) and 10% Tet System Approved Fetal Bovine 
Serum (Clontech, Germany) and grown on poly-D-lysine-coated plates. The growth 
conditions for N2A cells were similar to that of MN9D cells, except that they did not 
need coating. The growth conditions of the SH-SY-5Y cell lines were also the same 
except for the concentration of FBS, which was 20% instead of 10%. The PC12 cells 
were grown in RPMI medium supplemented with 10% horse serum, 5% FBS and 1% 
Penicillin/ Streptomycin (final concentration: 50U/mlPen. -50µg/ml Strep.) 
(Invitrogen, Germany). The freezing of the cells was done after detachment and 
centrifugation, followed by addition of freezing solution containing 10% DMSO 
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(Sigma, Germany) in FBS. Initially, cells were incubated on ice for 30min., frozen at -
20˚C for two hours in a paper towel, kept at -80˚C overnight to one week and then, 
they were transferred into liquid nitrogen at -180˚C for long-term storage. Thawing of 
the cells was done by immediate shaking in a 37˚ water bath and the cells were always 
centrifuged at 1000rpm for 5min. before re-growing. 
 
4. Expression of Engrailed in MN9D Cells, Tet-ON System 
 
For expression of En1, 
the TetON expression 
system was used 
(Gossen and Bujard, 
1992; Hermanson et 
al., 2003). Cells were 
transfected with the 
pTet-On vector using 
Lipofectamine PLUS 
(Invitrogen, 
Germany). An 
individual G418-
resistant colony was 
isolated, expanded, 
and screened for 
expression of the Tet-
inducible transcription 
factor. The En1 cDNA 
was cloned into the 
pRevTRE vector downstream of the Tet-regulated promoter elements. MN9D-Tet-On 
cells were co-transfected with pRevTRE-En1 and pTK-Hyg vectors using 
Lipofectamine2000 (Invitrogen, Germany). An individual hygromycin-resistant colony 
was isolated, expanded, and screened for the induction of En1 by doxycycline. En1 
expression and GFP expression were checked by western blot or by 
immunohistochemisty. En1 expression was induced by addition of 5µg/ml doxycycline 
 
-DOX
DAPI
+DOX
GFP En-1 DAPI  
Figure-1: Outline of the Tet-ON system (top)(adapted from 
www.clontech.com/clontech/tet/index.shtml) and expression of 
Engrailed and GFP in MN9D cells by Tet-ON (bottom). 
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(Clontech) to the culture medium. Neurotoxin treatment was done on ±Dox MN9D 
cells. The expression of En1 and GFP was checked, by immunohistochemistry (Fig. 1). 
 
5. Chemical Treatment 
 
List of the compounds and the toxins used in the pathway study, stock concentrations, 
using concentrations, storage conditions and treatment times are listed in Table-1. 
 
6. Cell Death/Proliferation Assay 
 
The cell death was quantified using CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Germany).  40µl of the 96 AQueous One Solution was 
directly added to cells with 1ml medium and after incubation at 37° for one to four 
 
 
Table-1: Specification of the chemicals, used in study of the pathway of cell death. The serum was 
withdrawn 24-2hrs., before application of the chemicals. The chemicals remained in the medium for 
entire duration of the treatment except for 6-OHDA where the treatment time was less than 15 minutes 
but the cells were analyzed after 24h. 
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hours, 100µl of the medium was transferred to 96 well plates and the absorbance was 
measured at 490nm using the Bio-Rad-550 Microplate reader. 
 
7. Small Interfering RNA 
7.1. Design and Preparation of siRNA Oligos 
 
For RNA interference experiments, either ready to use dsRNA oligos were used or 
they were produced by the Dicer method. For this method, after designing and cloning 
a 450-500bp fragment from the coding region of the desired gene into the pBluescript 
II SK(-) vector, which was digested from both sides (in separate tubes) and two sets of 
transcriptions from the two sides of the fragment were carried out for two hours in a 
total mix of 20µl, containing 1µg digested DNA (adjusted to 7µl), 4µl Trans 5X 
transcription buffer (Promega, Germany), 2 µl dNTP mix (New England Biolabs, 
Germany), 2µl 0.1M DTT (Promega, Germany), 1 µl T7 (or T3 or SP6) RNA 
Polymerase 2500 U 50 U/µl (GIBCO BRL) and 3.5 µl DEPC treated H2O. After 
transcription, the RNAse-free DNAse was added and the tubes were kept at 37°C for 
15min. The ssRNA were cleaned, using Qiagen RNeasy kit and the amount of ssRNA 
was measured. Equal amounts of the ssRNA were added to the annealing buffer (100 
mM NaCl, 20 mM Tris at pH 8.0, 1mM EDTA) and the mixture was heated up to 95°C 
for 3min. and then at 68° for 30min. followed by overnight cooling down to room 
temperature. The dicer digestion reaction to produce 21mers was carried out at 37°C 
by addition of the dicer enzyme and 10x reaction buffer (both from Stratagene, 
Germany). The cut dsRNA were purified, using a purification column specific for 
fragments smaller than 50bps (Millipore, Germany). The RNAi oligos were stored at -
20°C until transfection. 
The design of the 21mer ready to use RNAi oligos was carried out by using the online 
software at biomers.net in accordance with the protocol of Elbashir et al. (Elbashir et 
al., 2001). The sequence lied within the coding sequence of pbx-1, p75NTR, and 
NRAGE (Mage-D1). For p75, the sense sequence being 5’-
ACAGAACACAGUGUGUGAA(dTdT) and the anti-sense sequence, 5’-
UUCACACACUGUGUUCUGU(dTdT). The sense sequence for NRAGE 
oligonucleotide was 5’-UAACUUGAAUGUGGAAGAG(dTdT) and the anti-sense 
was 5’-CUCUUCCACAUUCAAGUUA(dTdT). For coupling with Penetratin-One 
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(QBiogene, France), the sense strand was modified with a thiol group on the 5’ end of 
the sense strand and for the purpose of detection of transfection, the anti-sense strand 
was labeled with FITC. 
 
7.2. siRNA Transfection 
 
The transfection reagents, HiPerfect (Qiagen, Germany), Ribojuice (Calbiochem, 
Germany), and Lipofectamine (Invitrogen, Germany) were used according to the 
manufacturers’ protocols and except for HiPerfect with a transfection efficiency of 
50% for primary neuronal cultures, these reagents could not achieve optimum 
transfection and therefore, Penetratin-1 was used. 
Penetratin-1 solution was reconstituted to 2mg/ml (=0.8mM) in sterile water. Stock 
solution of 20mM TCEP (tris-2-carboxyethyl phosphine from Pierce, Germany) in 
sterile RNAse/DNAse free water was made. SiRNA oligos were dissolved in 
RNAse/DNAse free sterile annealing buffer to a concentration of 900µM. 1µl TCEP 
was added to 224µl siRNA and incubated for 15min at room temperature. Then, 25µl 
Penetratin-1 was added, mixed and incubated for 5 min. at 65°C followed by 1 hour at 
37 C. The aliquots were frozen at -80°C. The Penetratin coupled siRNA oligos were 
heated to 65°C for 15min. and dissolved in complete growth medium. Then, it was 
added to cultures in different concentrations to minimize the toxicity with maximized 
transfection efficiency. For the siRNA of p75, 20µl of the Penetratin-siRNA mix was 
dissolved in 500µl medium. 
 
8. Immunocytochemistry and Immunohistochemistry 
 
The cover slips were fixed with 4% PFA and washed thoroughly with PBS. Fixed 
Cells were blocked in the blocking solution (10% FCS, 0.5% Triton, in 0.1M PB.) for 
one hour at room temperature. For DAB staining, 0.006% H2O2 was added to the 
blocking solution. After blocking, the cells were washed with PBS and put into the 
primary antibody/s, diluted into the blocking solution, overnight at 4°. After washing 
the cells with PBS, the cells were placed into the secondary antibody/s (also diluted in 
the blocking solution) for 2 hrs. at room temperature. After another wash with PBS, in 
some cases, to enhance the signal, the biotin-streptavidin system was used and 
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therefore the cells were covered with the tertiary, streptavidin conjugated, antibody 
diluted in PBS for one hour at room temperature. After washing the cells with PBS, 
they were treated for 5 min. with 4'-6-Diamidino-2-phenylindole (DAPI), diluted 
(1:50,000 in 0.1M PB). For the fluorescent staining, after a final wash with PBS, the 
cover slips were mounted using the Aqua Poly/Mount solution (Polysciences, 
Germany). In case of sheep anti-TH primary antibody, For the DAB color reaction, 
cells were treated with 0.1% DAB (3,3’-diaminobenzidine tetrahydrochloride, Sigma-
Germany) added to 0.1M PB solution in presence of 0.006% H2O2. 
For immunohistochemistry on the PFA fixed sections, the same procedure was used 
except for the number and duration of the washes, which were three times five minutes 
after each step. The antibodies, used regularly, were rabbit anti TH, at a dilution 
between 1:500 and 1:1000 (Chemicon, Germany), sheep anti TH at a dilution of 1:200 
(Chemicon, Germany), purified mouse anti Engrailed-4G11 at a dilution of 1:100 
(Developmental studies, Hybridomas Bank). The using concentration of polyclonal 
rabbit antibodies for most of the antigens was 1:500.  
 
9. Protein Lysis and Preparation 
 
Cells from cell lines were lysed and stored in 2x Laemmli buffer (2.5 mM Tris-HCl 
(pH 6.8), 25% glycerol, 2% SDS, 0.01% Bromophenol Blue, 710 mM beta-
mercaptoethanol). The midbrain total protein from was extracted from dissociated 
tissue using 2x Ripa buffer (50mM Tris-HCl, pH 7.4, 1% NP40, 0.25% sodium 
deoxycholate, 150mM sodium chloride, 1mM EDTA, 1mM PMSF, 1ug/ml aprotinin, 
1ug/ml leupeptin, 1ug/ml pepstatin, 1mM sodium orthovanadate, 1mM NaF) and 
diluted into Laemmli sample buffer. The subcellular protein fractions (from cytosol, 
membranes, nucleus, or cytoskeleton) were extracted using Qiagen’s Qproteome Cell 
Compartment kit in presence of protease inhibitor. 5 x 106 cells were centrifuged at 
500xg for 10min at 4°C. The cell pellet was re-suspended in 2ml ice cold PBS and 
centrifuged again (twice). The pellet was re-suspended in 1ml Extraction buffer CE1, 
incubated at 4°C for 10 min, and centrifuged at 1000xg for 10 min at 4°C. The 
supernatant was transferred and marked cytosolic protein and the pellet was re-
suspended in 1ml ice-cold extraction buffer CE2 and Incubated for 30 min at 4°C on 
an end-over-end shaker. The suspension was centrifuged 6000xg for 10 min at 4°C. 
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The supernatant was transferred and marked membrane/mitochondrial protein. 7µl 
Benzonase and 13µl distilled water were added to the pellet and incubated for 15 min 
at room temperature. 500µl ice-cold extraction buffer CE3 was added into the tube and 
Incubated for 10 min at 4°C on end-over-end shaker. The insoluble was centrifuged at 
6800xg for 10 min at 4°C. The supernatant was marked nuclear protein and the pellet 
was re-suspended in 500µl extraction buffer CE4. This suspension contained 
cytoskeletal fraction. For the first three portions, the extraction buffers CE1-3 
contained protease inhibitor. For precipitation of the protein, four volumes of ice cold 
acetone was added to protein samples and incubated for at least 15 min. at -20°C. The 
samples were centrifuged for 10 min at 12,000 x g at 4°C. The supernatant was 
discarded and the pellet was air-dried. The pellet was re-suspended in 2X Laemmeli 
buffer. All protein samples were stored at -80°C. 
 
10. Western Blot Analysis 
 
Stacking and running SDS polyacrylamide gels were prepared and placed in the 
Laemmeli running buffer (0.192M Glycine, 0.25M Tris base, 0.1% SDS). The samples 
were ran at 80v and then transferred to membrane at 4°C, using the semidry or wet 
transfer methods. The blot was blocked in (5% milk added to PBSt) for one hour to 
overnight at room temperature or 4°C, respectively. After three 5min. washes, primary 
antibodies, dissolved in 5% albumin fraction V solution (in PBSt) were added and left 
shaking from two hours to overnight at 4°C. The blots were washed with PBSt for 
three times for 5 to 10 minutes each and then they were placed into the secondary, 
peroxidase conjugated antibody solution for one hour at room temperature. After three 
times washing with PBSt, the blots were covered by ECL solution (GE Biomedicals, 
USA) consisting of 1x solution A and 40x solution B. After more than one-minute 
exposure to ECL solution, the blots were placed on the Heperfilm (GE Biomedicals, 
USA) and developed and fixed using respective solutions (Kodak, Germany). The 
noncommercial ECL was carried by using 10x the solution of 0.25mM luminal in 
0.1M Tris-HCl (PH 8.6) and 1x of 0.1mM Coumaric acid solution in DMSO mixed 
with 1.5ul per 5ml, 30% H2O2 solution. 
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11. Immunoprecipitation 
 
The basic protocol of the Protein-G Immunoprecipitation Kit (Sigma, Germany) was 
used. About 150000 cells were lysed, using 300µl IP buffer. The primary antibody was 
added to the lysis, the volume was adjusted to 600µl by addition of IP buffer, and 
transferred to the spin column. The column was placed in a end-over-end shaker 
overnight at 4°C. 30µl of the protein-G agarose beads were washed in cold 1X IP 
buffer by centrifugation at 12000 x g for 30 seconds. The supernatant was removed 
and the beads were re-suspended in 50µl IP buffer and added to the cell lysate. After 
2hrs of incubation at 4°C in the end-over-end shaker, the column was broken and 
centrifuged at 12000 x g for 30 seconds. The beads inside the column were washed 
nine times, using 700µl 1X IP buffer and centrifugation at 12000x g. The last wash 
was done using 0.1X IP buffer. 100µl 2x Laemmeli buffer was added to the beads and 
the beads were boiled (95°C) inside the closed column for 5min. The sample was 
spinned down at 12000 x g and stored at -80°C. 
 
12. In Situ Hybridization 
12.1. Digoxygenin Labeled In Situ   
12.1.1. Preparation of Digoxigenin labeled RNA Probes 
 
Sense and anti-sense RNA probes were generated by PCR amplification of 400 to 
1000bp fragments. After cloning of the desired fragment into the pBSK vector, it was 
linearized and incubated for 2hrs. at 37°C in 20µl transcription mix consisting of T7 
polymerase (Ferentas, Germany), Trans 5x buffer (Fermentas, Germany), 10x DIG 
labeling mix (Roche, Germany), 0.01 M DTT (Promega, Germany), and 1U/µl RNAse 
inhibitor (Promega, Germany). After transcription, 10U/µl RNAse free DNAse was 
added to the mix for 15min at 37°C. The DIG-probes were purified using the RNAeasy 
purification columns (Qiagen, Germany) or they were precipitated in 100µl TE, 1M 
LiCl, and 300µl 100% ethanol, for 30 min at -70˚C and then centrifuged at 14000rpm 
for 10 min. The pellet was washed with 80% ethanol, and re-suspended in 
TE/formamide (50µl: 50µl). After 10min. at 60˚C, the amount of RNA was measured 
by spectrophotometer (RNA 230 and 260 nm) and stored at –20°C.  
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12.1.2. Digoxigenin (DIG) Labeled In Situ 
 
The embryonic tissue were fixed overnight at 4°C in 4%PFA following by incubation 
in 30% sucrose in 0.1M PB solution at 4°C. The tissue was placed in OCT Tissue Tek, 
frozen, and cryostat sectioned. The adult tissue were fresh frozen in isopentane, pre-
cooled at -70°C and then, sectioned. After air-drying for at least 20min. (up to 3hrs), 
the sections were put into 4% PFA for 10min. then washed three time with PBS for 
3min. each, following by a 5 min. treatment with 1ug/ml proteinase-K in 50mM Tris 
and 5mM EDTA. The time of proteinase-K treatment for fresh frozen sections was not 
more than 1min.; The fixation and washing steps were repeated and the sections were 
treated for 10min. with acetylation mix, consisting of 3.25ml triethanolamine, 0.7ml 
acetic anhydride, in 250ml H2O. Then, the sections were washed three times for 5min., 
each, with PBS. 
The 400ng/ml digoxygenin labeled RNA probes were dissolved in hybridization 
buffer, consisting of 50%formamide, 5x SSC, 5x Denhardt’s, 250ug/ml baker yeast 
RNA, and 500ug/ml herring sperm DNA in H2O. Then, the probes were heated at 
80°C for 5min. and were put on ice. 100ul probe was used for incubation with each 
slide at 72°C overnight in a 5x SSC and 50% formamide humidified chamber. After 
overnight incubation, slides were submerged into 5x SSC to remove the cover slips 
and were placed into 0.2x SSC for 2 hours at 72°C followed by a room temperature 
wash with 0.2x SSC for 5min. The sections were treated with B1 buffer (100mM Tris 
PH=7.5, 150mM NaCl, in H2O) for 5min and then blocked for 1 hour with 10% goat 
serum in B1 Buffer. They were incubated overnight at 4°C with 1:5000 dilution in B1 
buffer plus 1% goat serum. The overnight anti-Digoxygenin, antibody treatment, was 
followed by three 5 min. washes with B1 buffer and one 5 wash with B2 buffer 
(100mM Tris PH=9.5, 100mM NaCl, 50mM MgCl2 in H2O). Then, the sections were 
left in NBT/BCIP solution (0.338ug/ml NBT and 0.35ug/ml BCIP in B2 buffer) for 3h 
to several days for color reaction. The DPX mounting preceded by air-drying the 
sections, and 3min. dehydration steps with 30%, 50%, 70%, 95% and 100% ethanol. 
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12.2. Radioactive Labeled In Situ 
12.2.1. Preparation of the Radioactive RNA Probes 
 
The transcription mix for radioactive in situ consisted of 4µl 5X transcription factor 
(Fermentas, Germany), 1µl 0.1M DTT, 1.5µl nucleotide mix (without UTP), 0.5µl 
RNAse inhibitor, 0.5µl digested DNA, 0.5µl T7 or T3 RNA polymerase, and S35 
labeled UTP (50UCi) and added H2O for a total volume of 20µl. After incubation at 
37˚C for 2hrs., 47µl H2O, 20µl yeast tRNA (10mg/ml), 1µl 1M DTT, and 1µl RNAse 
free DNAse were added to the mix and incubated for 15min at 37˚C.  The RNA probes 
were then precipitated by addition of 100µl H2O, 70µl 7.5M NH4OAc, 700µl 100% 
ethanol, and incubation at -70˚C for 10 min. After centrifugation at 14000rpm for 
10min, the supernatant was removed and the pellet was dried. The pellet was dissolved 
in a mix of 70µl formamide, 70µl H2O and 10µl 1M DTT. 1µl of the probe was used 
for measurement of the radioactivity, which had to be at least 400,000cpm/µl.  
 
12.2.2. Radioactive In Situ 
 
The mounted sections were pretreated with 4%PFA in PBS, and then they were 
washed with PBS for 3min twice. The slides were incubated at 2XSSC at 65˚C for 
30min. followed by a 1min. H2O wash. The sections were treated for 10min. with 
20µg/ml Proteinase-K, dissolved in TE (10mM Tris-PH=8 and 1mM EDTA, 200µl 
proteinase-K-20mg/ml, 400µl EDTA 0.5M and 2ml Tris 1M with added H2O up to 
200ml). The slides were put into a solution of 0.2% glycine in PBS for 30s. and 
washed for one min. twice in PBS. Then, they were fixed with 4% PFA for 20min. 
following by a wash of PBS for 3min. They were incubated in the acetylation mix 
(3.25ml triethanolamine and 0.7ml acetic anhydride in 250ml H2O) for 10min. After a 
three-minute wash with PBS, the sections were dehydrated through consecutive, 2min. 
treatments with 30%, 60%, 80%, 95% and 100% ethanol. After drying for 1hr, the 
slides were treated with 50,000,000cpm/ml RNA probe, dissolved in the hybridization 
mix containing 50% formamide, 10% Dextran, 1X Denharts, 0.3M NaCl, 10mM Tris 
PH=7.5, 10mM sodium phosphate PH=6.8, 5mM EDTA, 25mM DTT, and 50mM ß-
mercaptoethanol. The mixture was heated to 80˚C for 5min. and centrifuged for 1min 
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and then added on top of the sections. The slides were incubated at 55˚C overnight in a 
humidified chamber. After hybridization, the slides were washed with 5X SSC and 
20mM ß-mercaptoethanol, pre-heated at 55˚C for 30min. The cover slips were 
removed and the slides were washed twice with 2X SSC, 50% formamide, and 20mM 
ß-mercaptoethanol for 45min. at 65˚C.  The slides were placed at 0.5M NaCl/TE 
solution at 37˚C for 15min., followed by addition of 20µg/ml RNAse-A and treatment 
for 15 min. The slides were placed in a solution of 50% formamide, 1mM EDTA and 
20mM ß-mercaptoethanol at 55˚C for two hours, following by washes of 0.2X and 
0.2X SSC at 55˚C for 15 min. each. The pre-hybridization dehydration steps were 
repeated and the slides were dried for one hour. Hyperfilm (Kodak, Germany) 
exposure time was between one day and up to four weeks.  
 
13. Identification and Analysis of Transcription Factor Binding 
Sites 
 
The transcription factor binding site analysis and identification of the interspecies 
conserved sequences of mouse and human P75 (up to -10kb) was carried out, using the 
online computational tools at http://pga.lbl.gov/rvista.html. The global alignment file 
was generated by the AVID program. The TRANSFAC matrix library and the 
MATCH program were used to identify all transcription factor binding site (TFBS) 
matches in each sequence. Then, the global alignment and the sequence annotations 
were used to identify all aligned TFBSs present in the non-coding DNA. A second file 
was generated, containing aligned non-coding TFBS’s. DNA sequence conservation 
was determined by the hula-hoop module, identifying the TFBS’s, surrounded by 
conserved sequences and generated a data table. Finally, the data was customized by 
choosing for En1 as the transcription site to be visualized the TRANSFAC parameters 
were set to rVISTA’s default, 0.75/0.8. 
 
14. Luciferase Assay 
 
The luciferase reporter vector was constructed, using the suspected P75 promoter 
region. An 8kb piece, containing the first axon and 5000bp upstream, was cut, using 
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XhoI/BglII from the RP24-347P1 BAC clone. This piece was placed into the MCS of 
the pBluescript II (KS)+ vector. 6.4kb, between XhoI and XbaI restriction sites was 
cut and placed into pGL3 vectors with and without the SV40 enhancer element. En1 
containing N2A Tet-ON cells were grown in 24 well culture dishes, 48h after addition 
of Dox, the cells were transfected, using Lipofectamine2000, with the 6.4kb piece, 
cloned into PGL3 basic vector or into the vector containing SV40 enhancer and 
simultaneously with the Renilla control vectors. 24h after transfection, cells were 
washed with PBS and lysed by addition of 250µl passive lysis buffer to each well 
(PLB; Promega, Mannheim). After shaking the cells horizontally for 15 min at room 
temperature, an equal volume (250µl) of the Dual-Glo Luciferase reagent was added to 
the medium. After 10min. incubation at room temperature, the firefly luminescence 
was measured with a luminometer. For measuring the Renilla luciferase activity, Dual-
Glo, Stop and Glo Luciferase reagent was added within 4hrs after addition of Dual-Glo 
and the luminescence was measured within 2hrs.  The activity of firefly (Photinud 
pyralis) was normalized against the activity from Renilla (Renilla reniformis) 
luciferase and then normalized against the reading from the empty vector. 
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1. Involvement of the Mitochondrial Pathway of Apoptosis 
 
We had previously reported that loss of Engrailed expression causes activation of 
caspase-3 in mesDA neurons(Alberi et al., 2004; Sgado et al., 2006). Caspase-3 is the 
effector caspase of the extrinsic and intrinsic (mitochondrial) pathways of apoptosis(Li 
et al., 1997; Stennicke et al., 1998). Since multiple in vitro and in vivo experiments 
have shown that mesDA neurons, and in particular, the subgroup in the substantia 
nigra, are sensitive to apoptosis induced by mitochondrial dysfunction(Li et al., 1997), 
I examined the contribution of this pathway to the loss of mesDA neurons in EnDM 
embryos and nigral neurons of postnatal EnHT mice. I detected small, round TH-
positive cells with active caspase-9 and pyknotic, fragmented nuclei in the ventral 
midbrain of dying Engrailed-deficient E13 embryos. Similar to the null mutant 
embryos, mesDA neurons of EnHT mice also showed condense, fragmented nuclei 
along with activated caspase-9 during the postnatal stages of nigral cell loss (P21). The 
P21 EnHT nigral neurons also showed activation of caspase-3, similar to the EnDM 
mesDA neurons (Fig. 1)(Alberi et al., 2004; Sgado et al., 2006). 
 
 
Figure-1: Activation of caspases in TH positive mesDA neurons of Engrailed-deficient mice. 
Caspase-9 is activated in mesDA neurons of EnDM E13 embryos (a), E12 primary cultures of ventral 
midbrain (b) and P21 EnHT SN neurons (c). Caspase-3 is also activated in EnHT P21 nigral neurons. All 
TH positive cells with pyknotic nuclei showed caspase 3 and 9 activation. Scalebar=25µm. 
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To further investigate 
whether cell death in 
Engrailed-deficient mesDA 
neurons involves the 
mitochondrial pathway, I 
applied apoptosis-inhibiting 
peptides to E12 primary 
cultures derived from 
ventral midbrain. In culture, 
untreated EnDM mesDA 
neurons die between 24h 
and 72h after dissociation. 
The survival rate of EnDM 
mesDA neurons did not 
differ significantly from the 
untreated controls whether 
specific inhibitors for 
caspases-3, -9, or -8, or a 
general caspase inhibitor 
(Fig. 2) were applied. 
Additionally, the inhibition 
of Bax, a pro-apoptotic member of the Bcl-2 family (Sawada et al., 2003) also failed to 
rescue the Engrailed-deficient mesDA neurons (Fig. 2). To examine other mechanisms 
related to mitochondrial apoptosis in mesDA neurons, I also applied inhibitors to JNK 
and P53 (Anderson and Tolkovsky, 1999). Both did not change the survival rate 
significantly. 
 
2. Mitochondrial Dysfunction is Contributing but not the Sole 
Mechanism of Cell Loss 
 
Failure of the specific inhibitors of the intrinsic pathway to rescue Engrailed-deficient 
mesDA neurons from cell death suggested either lack of involvement of apoptosis or 
participation of one or more parallel independent molecular pathways. To elaborate on 
 
 
 
Figure-2: Effect of anti apoptotic reagents on E12 EnDM 
mesDA neurons. Treatment of EnDM cultures with inhibitors for 
caspases 3,8 and 9 as well as a pan-caspase inhibitor, the Bax 
mitochondrial translocation inhibitor, Ku70, a specific inhibitor 
of P53, Pfithrin-α, and JNK inhibitor, SP600125, induce no 
significant improvement on the survival rate of TH positive 
cells. The period of DA cell loss for untreated mutant cultures is 
between 24h and 72h (Alberi et al., 2004). The number of 
surviving cells in each case was normalized against the number 
of untreated EnDM cells at 24h. 
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these possibilities, I correlated the sensitivity of mesDA neurons to the induction of 
different pathways of programmed cell death to the level of Engrailed expression by 
using mesDA neurons, derived from embryos of two Engrailed genotypes, with wild-
type-like survival rate in vitro, i.e. En2-/- and EnHT (En1+/-;En2-/-). The ratio of pro- 
to anti-apoptotic members of the Bcl-2 family of proteins is believed to play a critical 
role in the intrinsic pathway by determining stability of the mitochondrial outer 
membrane (Hengartner, 2000). I, therefore, induced mitochondrial apoptosis via 
application of HA14-1 and chelerythrine chloride, specific inhibitors of the anti-
apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-XL, respectively(Tanaka et al., 
2004; Wang et al., 2000). 24 hours after treatment with HA14-1 and chelerythrine 
chloride, the rate of survival of mesDA neurons derived from E12 En2-/- embryos was 
on average 75.3 ± 6.8% and 92.7 ± 2.7% (p<0.001, n>15 for both), respectively, 
higher than their counterparts derived from EnHT littermates (Fig. 3, 5).  
The three most common reagents to induce cell death in mesDA neurons, MPP+, 6-
OHDA and rotenone(Dauer and Przedborski, 2003), cause cell death by induction of 
the mitochondrial pathway of apoptosis. They cause activation of caspase-9 and 
caspase-3(Kaul et al., 2003; Liang et al., 2004; Watabe and Nakaki, 2004). Having 
confirmed these observations in our culture system (Fig. 4), I explored the possibility 
that the sensitivity to these toxins may be linked to the level of Engrailed expression,  
 
 
Figure-3: Sensitivity of mesDA neurons to inhibitors of Bcl-2 and Bcl-XL. The rate of survival of 
the En2-/- mesDA neurons is more than their En1+/-;En2-/- (EnHT) littermate counterparts, in presence 
of HA14 and Chelerythrine chloride, the inducers of  mitochondrial apoptosis via inhibition of Bcl-2 
and Bcl-XL, respectively. For the exact numbers see Fig. 5. 
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Figure-4: Activation of caspases in neurotoxin treated mesDA neurons. Caspase-9 (A-C) and 
caspase-3 (E-G) are activated in wild type mesDA neurons, treated with MPP+, 6-OHDA or rotenone. 
Scalebar = 25µm. 
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 comparable to what I observed for HA14-1 and chelerythrine chloride. After 48 hours 
in culture, the rate of survival of mesDA neurons derived from En2-/- embryos was on 
average 124.5 ± 5.0% (p<0.001, n=12) higher than for their EnHT littermates after 
treatment with MPP+, while the higher dose of En1 had no or only a, comparatively, 
little effect after treatment with 6-OHDA or rotenone (3,4 ± 8,9% p=0.91, n=8 and 
20,8 ± 3,6% p=0.03 n=8, respectively) (Fig. 5). These data suggest that MPTP and 
Engrailed may act upon the same molecular pathway upstream of caspase-9, which 
differs from that of 6-OHDA or rotenone. To determine whether the protection exerted 
by the Engrailed proteins is specific to the mitochondrial pathway of apoptosis, I also 
employed the Apoptosis Activator-2(Nguyen and Wells, 2003), Prima-1(Bykov et al., 
2002), and the tumour necrosis factor (TNFα)(Adams, 2003). The first induces cell 
death by triggering apoptosome formation, the second by activation of p53 and the 
third, as a ligand of the TNF receptors, induces the extrinsic, receptor-mediated, 
pathway of apoptosis. In all three cases, the level of En1 expression did not have a 
significant influence on the survival rate of the neurons (-8.1 ± 6.0% (p=0.67) for 
AA2, 4.6 ± 6,2% (p=0.82) for Prima-1 and 5.1 ± 3.1% (p=0.48) for TNFα (n≥7 for all) 
(Fig. 5).  
 
3. Protective Effect of Engrailed Against Mitochondrial Insult 
and MPP+ Induced Cell Death in MN9D Cells  
 
To confirm the Engrailed dose dependent sensitivity of mesDA neurons to 
mitochondrial insult and to death, induced by MPP+, I carried out gain of function 
experiments, using the inducible Tet-On system to express En1 in the dopaminergic 
cell line MN9D(Choi et al., 1992). As in the primary cultures, En1 was protective 
against cell death, caused by application of MPP+ (42.4 ± 0.7% p<0.0001, n=23), 
chelerythrine chloride (46.7 ±1.3%, p<0.0001, n=10) and HA14-1 (32.4 ± 1.3%, 
P<0.0001, n=10). Contrary to the results for the dissociated primary neurons, En1 
improved the survival rate of 6OHDA and rotenone treated MN9D cells (36.9 ± 2.1%; 
p<0.0001, n=24 and 39.0 ± 2.0%; p<0.0001, n=32, respectively). The difference to the 
primary culture may be attributable to induction of high, non-physiological expression 
of En1 in the cell lines. For the other three reagents, the effect was, as in the primary  
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Figure-5: Sensitivity of mesDA neurons to inhibitors of Bcl-2 and Bcl-XL. Charts of primary 
cell cultures of En1+/+;En2-/- and En1+/-;En2-/- E12 ventral midbrain (a,b) and En1 inducible 
MN9D cells (c,d) after application of apoptosis inducing compounds are shown. Number of cells 
are normalized against untreated controls (a,c) or normalized against treated En1+/-;En2-/- cells 
(b) or treated non-induced MN9D cells (d) to show relative rescue effect in correlation with the 
level of En1 expression. Level of Engrailed expression inversely determines the sensitivity to 
MPP+ and to inhibition of Bcl-2 (by HA14) and Bcl-XL (by CC = chelerythrine chloride) in 
primary mesDA neurons and MN9D cells, whereas the outcome after application of the tumor 
necrosis factor alpha (TNFα), prima-1 and the apoptosis activator 2 (AA2) is independent of the 
level of En1 expression. 6-OHDA and rotenone behave differently in primary mesDA neurons 
(a,b) and MN9D cells (c,d). Error bars standard error. 6 ≤ n ≤ 27, *p ≤ 0.001, **p ≤ 0.0001.  
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cultures, 
negligible (-10.7 
± 4.7%, p=0.26 
for AA2, -8.3 ± 
5.2%, p=0.50 for 
Prima-1 and 1.0 ± 
7.4%, p= 0.95 for 
TNFα; n≥12 for 
all) (Fig. 5).  
Functional 
inhibition of Bcl-
2 and Bcl-XL, and 
application of 
MPP+ can induce apoptosis by release of cytochrome C from the mitochondrial inter-
membrane space into the cytosol(Cai et al., 1998; Deshmukh and Johnson, 1998). The 
protective effect of En1 against HA14-1, chelerythine chloride and MPP+ may be 
attributable to higher mitochondrial stability. To test this hypothesis, I compared the 
cytosolic and mitochondrial protein fractions of En1 expressing MN9D cells to non-
expressing cells. The proportion of cytochrome C in the mitochondria was always 
significantly higher after induction of En1 in MPP+ and untreated cells (76.1 ± 7.3%, 
p=0.03, n=3 and 41.6 ± 7.0%, p=0.005, n=3 respectively), whereas the total amount of 
cellular cytochrome C was unaltered (Fig. 6). In contrast, the proportional levels, in 
mitochondria and cytosol, of the apoptosis inducing factor (AIF), which causes 
caspase-independent mitochondrial apoptosis(Lorenzo et al., 1999), were independent 
of the level of En1 expression (data not shown), suggesting that Engrailed participates 
in regulation of mitochondrial stability via the cytochrome-C/caspase-dependent 
pathway of apoptosis rather than the caspase-independent pathway, represented by 
AIF. 
 
 
 
 
 
 
 
Figure-6: Inhibition of the release of cytochrome-C by Engrailed. 
Western blot analysis (a) of protein derived from mitochondrial vs. 
cytoplasmic compartments of MN9D cells, 72h after dox. induction of En1 
expression and MPP+ treatment for 24h. (starting at 48h) show that in MN9D 
cells, the release of cytochrome-C from the mitochondria is increased upon 
application of MPP+ and decreased by expression of Engrailed. The 
quantification of the bands from 3 individual experiments are shown in (b). 
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4. Elevated P75 Expression in Absence of Engrailed Causes 
Cell Death 
 
To identify the 
genes downstream 
of the Engrailed 
genes and to 
further elaborate 
on the death 
pathway in mesDA 
neurons, a 
genome-wide 
expression analysis 
was performed, 
using microarrays 
on En1 inducible 
N2A cell line (data 
not shown). The 
data suggested that 
the nerve growth 
factor receptor 
(Ngfr or P75) was 
a regulatory target 
of the Engrailed transcription factors. To confirm these preliminary results, I measured 
the amount of P75 in the cell line as well as in ventral midbrain tissue by quantitative 
RT-PCR. As a result of En1 induction in N2A cells, the endogenous expression of P75 
decreased by 10 fold (9.9 ±1.9% p<0.001 n=8). Likewise, in the embryo, ventral 
midbrain tissue derived from control littermates (En2-/-) expressed almost 2.5 fold less 
P75 (42% ± 14.0% p<0.001 n=6) than Engrailed double mutants (Fig. 7). The Western 
blot analysis confirmed these results; En2-/- control littermates expressed -74,4 ± 4.4% 
(p<0.001, n=3) and EnHT expressed -60,2 ± 8.8% (p=0.002, n=3) less P75 than the 
tissue from EnDM embryos (Fig. 7). 
 
 
Figure-7: Differential expression of P75 and expression of trk 
Receptors. Quantitative RT-PCR on the En1 expressing N2A cells vs. 
control, as well as ventral midbrain tissue of EnDM vs. En2-/- E12 
embryos, shows down-regulation of P75 expression in presence of En1 
(a). Western blot analysis of the ventral midbrain tissue shows a similar 
effect, where the amount of P75 protein in the EnDM ventral midbrain is 
significantly more than the EnHT or En2-/- (b,c). Addition of an inhibiting 
antibody of P75 (Rex) or siRNA knockdown of P75 rescued the EnDM 
mesDA neurons (d). The wild type-like neurons were unaffected (d). 
Numbers for EnDM or En2-/- are normalized against 24h controls. 
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To test whether P75 is directly regulated by Engrailed, the genomic sequence of mouse 
and human P75 gene was checked, using the rVISTA and MatInspector computational 
tools (Cartharius et al., 2005; Loots et al., 2002; Quandt et al., 1995) for possible 
evolutionarily conserved binding sites of Engrailed. Two binding sites were found, 
between  -140-180 and -250-340bp, within the human and mouse consensus promoter 
sequence (95% homology). Then, I performed a luciferase assay after cloning this 
 
Figure-8: Expression of neurotrophin receptors in mesDA neurons. P75, TrkB, TrkC and sortilin 
are expressed in the primary mesDA neurons derived from EnDM, or En2-/- embryos. The differential 
expression, detectable by Western blot, can not be detected by immunohistochemistry. Scalebars = 
25µm. 
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Engrailed double mutant mesDA neurons under BDNF is dose dependent, with a kD of 2.5 (b). Western 
blot of ventral midbrain, derived from EnDM EnHT or en2-/- E12 embryos shows that the expression of 
Trk receptors is not differential and the neurotrophins are not expressed at this age. 
sequence into the reporter 
vector and transfecting the 
vector into Engrailed 
expressing MN9D cells. The 
comparison between the 
luciferase signals, normalized 
against the internal Renila 
controls, showed a very small 
and insignificant difference in 
presence or absence of En1 
(Fig. 9), suggesting a 
secondary, indirect, mechanism 
for regulation of expression of 
P75.  
Since P75 can mediate cell 
death in neurons(Lu et al., 2005), I began to investigate whether its up-regulation in 
Figure-10: Protective role of neurotrophins 
and the non-differential expression of Trk 
receptors and neurotrophins. Treatment of 
the E12 ventral midbrain cultures, null for both 
Engrailed genes, for 72 hours, with saturating 
concentrations (>10ng/ml) of neurotrophins 
shows that BDNF, NT4 and NT3 are 
protective against loss of mesDA neurons due 
to  Engrailed  deficiency  (a).   The survival  of  
 
 
Figure-9: Luciferase activity of P75 consensus sequence 
in presence or absence of the En1. The renila vector was 
co-cotransfected and the value of luciferase activity was 
normalized against renila value. In addition to the renila, the 
values from a basic vector without the enhancer or P75 
consensus sequence was used as second control which were 
subtracted from the values of luciferase activity. The final 
values from the enhancer and normal vectors were 
normalized against the –Dox samples. 
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Engrailed mutants is causal to the cell death. 
To lower P75 expression in Engrailed double 
mutant mesDA neurons, I applied P75 
specific Penetratin-coupled siRNA 
duplexes(Davidson et al., 2004) to the 
ventral midbrain cultures. 72h after the 
transfection, the total P75 protein was 
reduced by 83.2 ± 6.3% (p=0.05, n=3) and 
the survival rate increased from 7.5 ± 1.24% 
to 25.1 ± 2.1% (p<0.001 n=16) (Fig. 3d). To 
complement this experiment, I interfered 
directly with the function of P75 by applying 
an inhibiting antibody (Rex)(Kruttgen et al., 
1998) to the medium. This antibody also 
increased the survival rate to 34.8 ± 4.6% 
(p<0.001, n=6). These data suggest that up-
regulation of P75 is a direct cause for the 
apoptotic cell death of Engrailed-deficient 
mesDA neurons. 
P75 mediates dual, opposing, functions of 
survival and death, controlled by presence or 
absence of neurotrophins. For anti-apoptotic 
function, neurotrophins require their cognate 
Trk receptors as heterodimerization partners 
for P75(Lu et al., 2005). In order to assess a 
potential role of the Trk/P75 system during 
the course of cell loss, I determined the 
expression of Trk-receptors in E12 mesDA 
neurons. TrkC and TrkB and , but not TrkA, 
were detectable by immunohistochemistry 
and Western blot at equal levels in wildtype 
and EnDM mutants (Fig. 8).  
 
 
Figure-11: Differential activation of 
Erk1/2. Western blot on the protein, derived 
from ventral midbrain of mutant E12.5 
embryos shows a significant reduction in 
phosphorylation of Erk1/2 in absence of the 
Engrailed genes (A,B), while the level of 
expression of Erk1/2 is unaltered in different 
genotypes (I). The antibodies against 
phosphorylated form of other MAPK’s, JNK 
and P38 or the upstream RAF-1, also did not 
detect any significant difference amongst 
different genotypes of Engrailed (I). 
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Figure-12: Differential phosphorylation of Erk1/2 in surviving vs. dying mesDA neurons and the 
survival mediating role of Erk1/2. While total Erk1/2 protein is present in mesDA neurons of both 
genotypes (a,b), P44/42 (Erk1/2) is phosphorylated in mesDA neurons, derived from En2-/- E12 ventral 
midbrain (c) but the activation of Erk1/2 is absent in mesDA neurons of their Engrailed double mutant 
(EnDM) littermates (d),. Erk1/2 becomes active in EnDM mesDA neurons, after treatment with the survival 
inducing neurotrophins, BDNF, NT4 and NT3 (e-g) or in mesDA neurons, where P75 is knocked down by 
Penetratin-coupled oligonucleotides (h). Presence of GDNF, TGF-ß or GDF15 did not induce activation of 
Erk1/2 in EnDM mesDA neurons (data not shown). Scale bars = 25µm. 
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The up-regulation of P75 and presence of the Trk-receptors suggested that the 
Engrailed deficiency introduces a neurotrophin requirement to the E12 mesDA 
neurons, which cannot be satisfied at this age, since the neurotrophins, specific to TrkB 
and TrkC, i.e. BDNF, NT4 and NT3, are not expressed in the E12 ventral midbrain as 
opposed to the adult (Fig. 10). To test this hypothesis, I applied saturating 
concentrations of BDNF, NT4 and NT3 to ventral midbrain cultures. After 72 hours, 
50.2 ±2.9% (p<0.0001, n=27), 42.3 ±10.1% (p<0.001, n=9) and 26.0 ±3.5% (p<0.001, 
n=9), respectively, of the otherwise dying EnDM mesDA neurons survived (Fig. 10). In 
contrast, application of the TrkA specific ligand, NGF, did not change the survival rate 
significantly. To validate the specificity of BNDF, NT3 and NT4, I applied to the 
mutant cultures GDNF, GDF-15 and TGF-ß, all of which are demonstrated survival 
factors for mesDA neurons(Blum, 1998; Strelau et al., 2000; Tomac et al., 1995). 
Similar to NGF, none of them could prevent death of the Engrailed-deficient mesDA 
neurons (Fig. 10). Furthermore, the linear dose-response trend-line of the survival 
effect of BDNF (Fig. 10) indicated a Kd value of approximately 2.5nM which 
corresponds with the reported affinity of BDNF to TrkB and P75(Barker, 2004). 
 
5. The Survival-Mediating Role of Extracellular Signal 
Regulated Kinase1/2 (Erk1/2) 
 
The survival function of neurotrophins has been mainly attributed to two downstream 
pathways, the extracellular-signal-regulated kinase-1/2 (Erk1/2) and 
phosphatidylinositol-3 kinase (PI-3K) pathways(Hetman and Xia, 2000). As the next 
step, I examined whether these pathways play a role in arbitrating the effect of 
neurotrophins in Engrailed-deficient mesDA neurons and whether they intersect with 
the molecular events regulated by Engrailed expression. Therefore, I studied activation 
of the two pathways, using antibodies against the phosphorylated forms of Erk1/2 and 
Akt(Hetman and Xia, 2000). Immunohistochemistry showed that while total Erk1/2 
protein was present in, both, En2-/- and EnDM mesDA neurons, it was activated only in 
the wild type-like cells and not in EnDM mesDA neurons (Fig12). Western blot analysis 
of ventral midbrain tissue showed a similar effect; Erk1/2 activity in E12 ventral 
midbrain tissue of EnDM embryos was reduced by 66.8 ± 18.2% (p=0.02, n=3) in 
comparison to their En2-/- littermates. In contrast to Erk1/2, I did not detect 
Results 
 
 
62 
differential activation 
of AKT in the Western 
blot (Fig. 11). 
Additionally, signs of 
differential activation 
of the other 
components of the 
MAPK pathways, i.e. 
JNK or P38 could not 
be detected (Fig. 11). 
The loss of Erk1/2 
phosphorylation in the 
Engrailed double 
mutant mesDA 
neurons suggested that 
the neurotrophin survival- and p75 death-signals lead to differential activation of this 
pathway. To investigate this, I examined the state of activation of Erk1/2 in EnDM 
mesDA neurons after application of the survival inducing neurotrophins. The addition 
of BDNF, NT4 and NT3, and the knock-down of p75 by siRNA oligonucleotides all 
caused phosphorylation of Erk1/2 in EnDM mesDA neurons (Fig. 12), however, Erk1/2 
was not activated after application of NGF, GDNF, TGF-ß or GDF-15 (data not 
shown). If the activation of Erk1/2 is part of the molecular cascade, essential for  
 
Figure-13: Erk1/2 inhibition and survival. The survival effect of 
neurotrophins, Rex or siRNA of P75 is abolished when the double 
mutant cultures are concurrently treated with 400nM of a specific 
inhibitor of MEK1/2, U0126 (K). The inhibitor of MEK did not have 
any effect on En2-/- mesDA neurons at this concentration. The 
increase in the amount of inhibitor to 1µM also killed the wild type-
like neurons. 
 
Figure-14: Inhibition of Erk1/2 by U0216. The inhibition of Erk1/2 by U0126 for three days, at 
concentrations as low as 500nM is detrimental to mesDA neurons. A marginal dose of U0126 was 
chosen for inhibition of Erk1/2 in EnDM mesDA neurons.    
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Figure-15: P75 knockdown by siRNA causes Erk1/2 phosphorylation. Immunohistochemistry on 
E12 primary cultures, shows expression of P75 in TH positive and other cell populations of En1+/-
;En2-/- embryos (A). The expression is significantly reduced in siRNA in cultures where P75 is 
knocked down by Penetratin-coupled RNA oligonucleotides, 48h after transfection (B). Western blot 
analysis of P75 RNAi, using Penetratin-coupled oligonucleotides shows an 85% reduction in P75 
protein level (C, right lane) or 65% reduction in uncoupled oligos, transfected by Hiperfect (C, middle 
lane). The decrease in the level of p75 in primary midbrain cultures causes an increase in 
phosphorylation of Erk1/2 (C). Measuring the bands from western blot shows the inverse correlation 
between expression of p75 phosphorylation of Erk1/2 (D). 
 
survival of mesDA neurons and is inversely correlated to the cell death signaling, 
caused by the up-regulation of P75, then inhibition of the Erk1/2 pathway should 
interfere with the rescue effect of the neurotrophins and of P75 inhibition or silencing. 
To test this, I concurrently treated the cultures with U0126, an inhibitor of, the 
MAPKK upstream of Erk1/2, MEK1/2 (Duncia et al., 1998) at a concentration 
(400nM) sub-toxic to wild type-like mesDA neurons. Increase of the concentration to 
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1µM, was lethal to mesDA neurons after treatment for 72hrs (Fig. 13). The inhibition 
of Erk1/2 by U0126 significantly reduced the rescue effect for all three survival 
factors; from 42.2 ± 3.1% to 11.7 ± 3.5% (p=0.002) for BDNF, from 34.7 ± 4 .7% to 
8.3 ± 2.7% (p<0.0001) for Rex and from 25.4 ± 2 .7% to 10.8 ± 1.9% (p=0.009) after 
P75 silencing (control mutant 4.2 ± 2.2% p=0.01 n ≥ 3 for all experiments) (Fig.  14). 
To elaborate further on the correlation between the expression of P75 and the state of 
phosphorylation of Erk1/2, I silenced the P75 expression in EnHT ventral midbrain 
culture by RNAi, using two methods with different transfection efficiencies 
(Penetratin-coupled oligos and the lipophilic transfection reagent, HiPerfect). The 
former reduced the P75 expression levels on average by 82.2 ± 6.3% (p=0.05, n=3) 
and the latter by 63.3 ± 2.0% (p=0.011, n=3). This, in turn, caused 8.64 ± 1.45 
(p=0.008, n=3) fold and 6.09 ± 1.40 (p=0.01, n=3) fold increase, respectively, in the 
phosphorylation of Erk1/2 (Fig. 15) demonstrating that P75 expression and activation 
of Erk/2 are inversely correlated to each other. 
 
6. Reduction in Activation of Erk1/2 by Neurotoxins  
 
Lack of activation 
of Erk1/2 in the 
EnDM mesDA 
neurons, correlated 
with high 
expression of P75 
shows that Erk1/2 
is a survival-
inducing pathway 
for mesDA 
neurons. I also demonstrated that the specific inhibition of this pathway causes death 
of the neurons. To test whether deactivation of the pathway is a general phenomenon 
in the dying neurons, I checked the activation of Erk1/2 in cells, treated with mesDA-
specific neurotoxins. Immunohistochemistry on wild type primary neurons derived 
from of E12 embryos showed that after 24hour neurotoxin treatment, phosphorylation 
of Erk1/2 was significantly reduced in mesDA neurons (Fig. 16). In MN9D cells the  
 
Figure-16: Deactivation of Erk1/2 in presence of neurotoxins. 
Treatment of primary mesDA neurons with MPP+ decreases the Erk1/2 
activation (A).  
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level of phosphorylated Erk1/2, 
comparing to that of untreated, En1 
expressing cells was 47%, 46% and 
36% in case of treatment by MPP+, 
6-OHDA or rotenone, respectively. 
The expression of Engrailed for 
48hrs., prior to and during the 
application of neurotoxins preserved 
the level of activation of Erk1/2 to 
71%, 62% and 54% respectively 
(Fig. 17). These data confirm the 
direct correlation between the 
expression of Engrailed and 
activation of Erk1/2 in primary 
mesDA neurons and suggest 
reduced activation of Erk1/2 in the 
cytoplasm, as a general vulnerability 
factor, common to the mesDA 
specific models of cell death.  
 
7. Activation of c-Jun in Axonal Beadings 
 
Western blot analysis showed that the death-mediating MAPK pathways were not 
differentially affected by the expression of Engrailed. Immunohistochemistry to detect 
phosphorylation of P38 and JNK also did not show differential activation, and similar 
 
 
Figure-17: Deactivation of Erk1/2 in presence of 
neurotoxins. Treatment of primary mesDA neurons 
with MPP+, 6-OHDA, and rotenone in MN9D cells 
decreased the activation of Erk1/2 while expression of 
En1 inhibited this effect (B).  
 
 
 
Figure-18: Activation of c-JUN in axonal beadings of mesDA neurons. While the activation of c-
JUN is seen in the cell bodies of some neighboring cells, its phosphorylation in mesDA neurons 
happens, exclusively, in the axonal beadings. Scale bar=25µm  
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to phosphorylated Erk1/2, they were activated in the cell bodies and axons. However, 
the activation of c-Jun, downstream MAPK of JNK, in the primary cultures of mesDA 
neurons was exclusive to axons and to the axonal beadings of mesDA neurons, while 
present in the cell bodies of some neighboring cells (Fig. 18). The beadings in nerve 
fibers are dynamic structures, considered as signs of axonal degeneration or culture 
artifacts (Ochs et al., 1997). The phosphorylation of c-JUN, as a pro-apoptosis event, 
in axonal beadings of mesDA neurons may suggest a mechanism for axonal 
degeneration in mesDA neurons. 
 
8. Miscellaneous Results 
8.1. Differential Expression of NRAGE by mesDA Neurons 
 
The interaction of intracellular factors with P75 is a determinant of its role, especially 
in neuronal apoptosis. Several molecules have been identified as intracellular binding 
partners of P75. Among the factors, interacting with the death domain of P75 and 
facilitating apoptosis, is a member of the melanoma associated antigen gene (MAGE) 
 
Figure-19: NRAGE expression and regulation by Engrailed. Dig In situ hybridization for TH (A)and 
NRAGE (B) on parallel sections of wild type adult mesDA neurons and Western blot analysis plus 
quantification of E12.5 ventral midbrain tissue derived from embryos with different genotypes of 
Engrailed (C).  
Results 
 
 
67 
family, MAGE-D1/ NRAGE (Salehi et al., 2000). The apoptotic activity of NRAGE is 
mediated via activation of JNK, cytosolic accumulation of cytochrome C, activation of 
Caspases-3, -9 and -7, and caspase-dependent cell death (Salehi et al., 2002). Although 
the expression, and therefore function, of NRAGE is not limited to P75 expressing 
neurons, all cells that express p75 also express NRAGE (Barrett et al., 2005). I could 
detect expression of NRAGE in a subpopulation of wild type adult mesDA neurons by 
in situ hybridization (Fig. 19). Western blot analysis on E12 ventral midbrain tissue 
showed that the expression of NRAGE in En1+/-;En2-/- and En1+/+;En2-/- was 54% 
and 34% of the EnDM, respectively. A comprehensive study of the function of NRAGE 
in mesDA neurons is still missing but these findings suggest an apoptotic role for 
NRAGE in mesDA neurons, with a possible connection to the Engrailed genes.   
 
8.2. Expression of Faim2/Lfg in the Midbrain 
 
The microarray study of Engrailed-expressing N2A cells showed that the expression of 
Fas apoptotic inhibitory moledule-2 (Faim2/LFG/NMP35) was increased in presence 
of En1. Localized at postsynaptic sites and in dendrites, Faim2 inhibits Fas-mediated, 
but not the TNF induced, extrinsic apoptosis (Schweitzer et al., 2002; Somia et al., 
1999). Furthermore, Faim2 overexpression in cerebellar granule neurons makes them 
resistant to death by Fas ligand via activation of PI3K (Beier et al., 2005). Here I show 
that Faim2 is widely expressed in the midbrain and in mesDA neurons (Fig. 20). A 
study about the possibility of involvement of Fas mediated apoptosis and Faim2 in the 
 
Figure-20: Expression of Faim2 in mesDA neurons and in Midbrain. Dig In situ hybridization for 
TH (A)and Faim2 (B) on parallel sections of wild type adult midbrain shows that Faim2 is expressed 
in the nigral neurons as well as the neighboring tissue. 
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death of Engrailed-deficient mesDA neurons is still missing. 
 
8.3. Expression of ErbB4 in Nigral mesDA neurons 
 
A transmembrane receptor tyrosine kinase (RTK), erythroblastic leukemia viral 
oncogene homolog 4 (ErbB4), is expressed in the mesDA neurons of rats. Its 
expression is diminished upon application of 6-OHDA (Steiner et al., 1999). The 
ligand, which preferentially binds to ErbB4, Neuregulin1-beta, evokes overflow of 
striatal dopamine, upon injection supranigrally (Yurek et al., 2004). To study the role 
of ErbB4 in the midbrain, in addition to development of a brain specific conditional 
mouse, we studied the expression of erbB4 in the mouse ventral midbrain. I used DIG 
and radioactive in-situ hybridization to study the expression of ErbB4 in 6 month-old 
mice ventral 
midbrain. ErbB4 
was present in the 
SN and a 
subpopulation of 
mesDA neurons in 
the VTA. The 
expression was 
missing from RRF 
(Fig. 21). Despite 
the lack of deficits 
in the cellular, 
physiological or 
biochemical 
composition of 
nigro-striatal 
system of 
conditional mice 
for ErbB4 (Thuret 
et al., 2004), 
 
Figure-21: Expression of ErbB4 in mouse mesDA neurons. The 
radioactive in situ hybridization shows that the expression of ErbB4 is 
limited to SN and a subpopulation of VTA neurons(Thuret et al., 2004).  
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a)                                                                                                                                                         
 
                         mesDA neurons                                           MN9D cells                                     EnDM 
b) 
 
                        mesDA           MN9D 
 
further study of ErbB4’s function could be of value due to the specificity of its 
expression to SN. 
 
8.4. Inhibition of K-ATP Channels and the Survival of mesDA 
Neurons 
 
ATP sensitive potassium (K-ATP) channels are octarmeric proteins consisting of two 
types of subunits, being members of Kir6 and sulphonylurea receptor (SUR) family. 
They activity of these channels depends on the intracellular level of ATP/ADP and, 
therefore, dependent upon the metabolic state of the cell (Liss and Roeper, 2001). The 
Figure-22: Rescue effect of tolbutamide on mesDA 
neurons treated with neurotoxins. Tolbutamide 
increased the rate of survival of primary mesDA neurons, 
treated with rotenone while it increases the rate of 
survival of MPP+ treated MN9D cells. Tolbutamide did 
not have an effect on EnDM neurons (A). The increased 
survival rate, normalized against the neurotoxin treated 
(without tolbutamide) is also shown (B). 
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expression profile of the subunits of these channels also defines their function in 
different neuronal populations. For instance the DA neurons in the SN show 
alternative co-expression of SUR isoforms with Kir6.2 and this alternative expression 
defines the sensitivity of the K-ATP channels to metabolic inhibition (Liss et al., 
1999). Additionally, the inactivation of Kir6.2 has been shown to selectively affect the 
electrophysiological activity of SN neurons and rescue of these neurons from MPTP 
intoxication or weaver mutation (Liss et al., 2005). I examined the effect of inhibition 
of K-ATP channels on the death, induced by MPP+, 6-OHDA or rotenone in primary 
mesDA neurons and MN9D cells by addition of tolbutamide (Stanford and Lacey, 
1995). Addition of tolbutamide to primary cultures and MN9D cells produced mixed 
results. In primary neurons, the significant difference was in rotenone-treated cells 
where in presence of tolbutamide, the rate of survival increased from 32±2% to 
52±6%(P=0.05). On the other side, in MN9D cells, by presence of tolbutamide, the 
rate of survival of MPP+ treated cells increased from 45±1% to 55±2% (P<0.001) 
comparing to untreated controls. The rate of survival of EnDM neurons did not change 
upon application of tolbutamide (Fig. 22). These results suggest that while inhibition 
of the hypo-activity of mesDA neurons via depolarization of the cells by blocking of 
the K-ATP channels can delay or inhibit the neurotoxin-induced cell death, it is not 
sufficient to rescue the mesDA neurons from dying because of Engrailed deficiency in 
the EnDM embryos. Since the cell death in EnDM is more acute and pronounced than 
other genotypes, the blocking of these channels might be beneficial to the En1+/-;En2-
/- adult mice where the phenotype is restricted to the SN neurons and the cells loss is 
slow and progressive.  
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The specific loss of mesDA neurons in EnDM embryos and the gradual, postnatal loss 
of nigral DA neurons in EnHT mice, is reminiscent of PD. Therefore, study of the 
mechanisms underlying cell death, attributable to the lack of Engrailed genes, may 
provide insight into the etiology of the disease. In this study, I provide evidence that 
the dose of Engrailed expression in mesDA neurons determines their sensitivity to 
mitochondrial insult, likely due to changes in the stability of the mitochondrial outer 
membrane and resulting in an increase in cytosolic cytochrome C and activation of 
caspase-9. Furthermore, I show that cell death, triggered by the loss of Engrailed 
expression in this neuronal population, is a result of an increase in P75 expression and, 
consequently, the absence of Erk1/2 activation. The apoptotic outcome of P75 up-
regulation can be counteracted by addition of neurotrophins, specific to TrkB/C or 
siRNA knock down of p75, suggesting that the elevated P75 expression in the E12 
EnDM embryos introduces a neurotrophin dependency, lacking from the wild type mice 
at this age. According to these results, Engrailed-deficiency causes cell death via two 
mechanisms of P75-mediated apoptosis and mitochondrial dysfunction. Taken 
together, in presence of the Engrailed genes, suppression of P75 and activation of 
Erk1/2 are parts of the same survival pathway that may, ultimately, protect cells from 
mitochondrial dysfunction and the intrinsic pathway of apoptosis. 
 
1. Involvement of the Mitochondrial Pathway of Apoptosis 
 
A strong body of evidence suggests reduced activity of the mitochondrial complex-I 
(Dauer and Przedborski, 2003), production of ROS and impairment of integrity of the 
mitochondrial membrane as parts of the process, leading to demise of mesDA neurons 
in PD (Fiskum et al., 2003). Apoptosis, in these neurons, is a consequence of interplay 
of these events from one side, and the classical mitochondrial pathway of apoptosis, 
involving the Bcl-2 family members, pro apoptotic molecules such as cytochrome C, 
AIF and the caspases, from the other side (Nicotra and Parvez, 2002). The connectivity 
of these two mitochondrial mechanisms is supported by the evidence that the chronic 
application of MPTP, as an inhibitor of complex-I which causes production of ROS, 
induces release of cytochrome-C from the mitochondrial intermembrane space by 
involvement of the Bcl-2 family members (Perier et al., 2005). The protective effect of 
Engrailed expression against MPP+ as well as against inhibitors of Bcl-2 and Bcl-XL, 
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shows a connection between Engrailed-deficiency and both of these mitochondrial 
processes and therefore, a possible relevance to etiology of PD. The activation of 
caspases 3 and 9 in E12 EnDM and P20 EnHT mesDA neurons and the inhibition of 
release of cytochrome C into the cytosol, by the Engrailed genes, further support the 
involvement of the mitochondrial pathway of apoptosis in death of EnDM mesDA 
neurons. 
Mitochondria can give rise to both, Caspase-dependent and –independent, pathways of 
apoptosis, depending on the release of cytochrome C or AIF, respectively (Cai et al., 
1998; Li et al., 1997). Our data are in support of the contribution of caspase-dependent, 
rather than caspase-independent pathway to death of the Engrailed-deficient mesDA 
neurons, especially since, contrary to cytochrome C, the release of AIF from the 
mitochondria to cytosol is not affected by the level of expression of Engrailed. If the 
cell death in EnDM neurons is caspase-dependent, failure of caspase inhibitors to rescue 
these neurons, suggests two possibilities that either the mitochondrial apoptosis is not 
essential to death of the neurons, or multiple pathways of apoptosis/cell death are 
involved.  
Our experiments did not indicate involvement of necrosis and plasma membrane 
damage, detected by propidium iodide (data not shown), and the only criterion to 
detect cell death was the presence of pyknotic nuclei.  In PD patients and in animal 
models of the disease, also the data strongly support apoptosis rather than other forms 
of cell death.  If the apoptotic criterion for detection of cell death to be accepted, since 
all of the E13 EnDM and P20 EnHT mesDA neurons with pyknotic nucleus show 
activation of both caspase-3 and -9, and since the Engrailed expression clearly affects 
the mitochondrial events such as release of cytochrome C, caspases are part of the 
signaling cascade and mitochondrial apoptosis has a role in the death of mesDA 
neurons but, it is downstream of the survival/death decision making point and once 
passed that point, cells employ multiple means, and often shift to different modes or 
pathways of cell death, to die. This is also the prevailing view about involvement of 
apoptosis in PD and its animal models (Tatton et al., 2003). 
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2- Mechanistic Difference Between MPP+ and 6-OHDA or 
Rotenone 
 
While inhibition of complex-I of the mitochondrial respiratory chain is a key function, 
shared by MPTP, 6-OHDA and rotenone (Schober, 2004), and caspases-3 and -9 are 
activated in mesDA neurons treated by all three toxic models, there is evidence 
suggesting that the molecular mechanisms of cell death are different (Choi et al., 1999) 
and the differential effect of expression of Engrailed on death, induced by each of the 
toxins, suggests different mechanisms. Exclusivity of the protective effect of Engrailed 
against treatment with MPP+ and not 6-OHDA or rotenone in primary mesDA neurons 
indicates that MPP+ and Engrailed converge on the same molecular mechanism which 
is not affected or shared by the other neurotoxins. Taking the protective effect of 
Engrailed against Bcl-2 and Bcl-XL inhibitors, HA14 and chelerythrine chloride, into 
account, also considering the opposing functions of Engrailed and MPP+ in inhibiting 
and inducing the release of cytochrome C from the mitochondria, it is highly possible 
that the intracellular site of action of MPP+ and Engrailed is the mitochondria and their 
functional point of convergence is permeability of the outer membrane. 
These results were in disagreement with the outcome of the gain of function 
experiments in MN9D cells, where induction of Engrailed expression caused 
protection against treatment with all three neurotoxins. The disparity between the two 
sets of data can be either due to induction of abnormally high, non-physiological 
expression of En1 in MN9D cells, or because of the small difference in expression of 
En1 between EnHT and En2-/- (in primary cultures). The second assumption can be 
only tested by comparison of the rate of survival of En2-/- mesDA neurons with that of 
EnDM, but since the survival period of the EnDM mesDA neurons is only 72 hours, 
during which, the cells are undergoing cell death, this comparison is not possible. It 
can be concluded that in primary neurons, doubling the En1 expression level affects 
only the death, induced by MPP+ and therefore, it is likely that the mechanism of cell 
loss, due to Engrailed deficiency, is similar to that of MPP+ and not to the other 
neurotoxins, while the possibility of effectiveness of Engrailed (in high doses) as a 
rescue factor against all three neurotoxins is still there. 
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3- Lack of Involvement of TNF and P53-Mediated Apoptosis 
 
Despite the evidence supporting involvement of the extrinsic pathway, the 
mitochondrial pathway of apoptosis is the prominent mode of cell death of mesDA 
neurons (Vila and Przedborski, 2003a). In agreement with this notion, I found that the 
level of expression of Engrailed in primary neurons and MN9D cells does not affect 
the survival rate in presence of TNF-α, representing the extrinsic pathway. The rate of 
survival of cells, dying by P53 activation, also, was not affected by the dose of 
Engrailed. Furthermore, pifithrin-α, an inhibitor of P53, a potent survival factor 
against MPTP treatment (Duan et al., 2002), could not rescue the EnDM neurons, 
suggesting a P53-independent role for the Engrailed genes.  
P53 is a transcriptional and posttranscriptional regulator of the Bcl-2 family members 
and P53-induced apoptosis is mediated via regulation of the pro- and anti-apoptotic 
members of this family, including Bax (Tobiume, 2005; Wu and Deng, 2002). The 
protection of mesDA neurons and improvement of behavioral outcome in MPTP-
treated mice via inhibition of P53 (by pifithrin-α) is attributed to suppression of 
increased expression of Bax (by MPTP) (Duan et al., 2002). Taken together with the 
fact that addition of KU70, an inhibitor of the mitochondrial translocation of Bax 
(Sawada et al., 2003), could not rescue the dying EnDM neurons, the expression and 
mitochondrial translocation of Bax, which are required for its apoptotic function 
(Nechushtan et al., 2001), do not contribute to the higher sensitivity of the 
mitochondria in Engrailed-deficient mesDA neurons. 
Several studies have shown that expression of P53 and its activity is affected by 6-
OHDA-treatment in dopaminergic neurons. In PC12 cells and in the SNpc of rats, the 
P53 cellular content increases by application of 6-OHDA (Blum et al., 2001; Blum et 
al., 1997). These data show that 6-OHDA-induced cell death is P53 dependent and the 
lack of response of cell death, induced by either of them, to the level of Engrailed 
expression confirms that Engrailed and 6-OHDA may act upon different molecular 
pathways.  
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4- High Expression of P75 is Causal to Loss of Engrailed-
Deficient mesDA Neurons 
 
High expression of P75 causes apoptosis in various neuronal populations via activation 
of the MAPK’s and the mitochondrial pathway (Bhakar et al., 2003; Bunone et al., 
1997; Rabizadeh et al., 1993). P75-mediated apoptosis can also be triggered 
extracellularly by addition of pro-neurotrophins (Lee et al., 2001; Lu et al., 2005; Teng 
et al., 2005). In this work, I show that the increase in the protein level of P75 is directly 
correlated with the decrease in expression level of Engrailed. This increase is 
responsible for the death of EnDM mesDA neurons, since the functional inhibition of 
P75 by Rex, or its knockdown by siRNA or addition of neurotrophins, BDNF, NT4 
and NT3, significantly increased the rate of survival. The death signaling of P75 can be 
activated, extracellularly, by addition of pro-neurotrophins or as a result of interaction 
of death inducing molecules with the intracellular death domain of P75 (Barrett, 2000; 
Lee et al., 2001; Nichols et al., 1998). Although the cause of P75 mediated apoptosis in 
mesDA neurons remains unknown, one possibility is the changes in expression of 
intracellular molecules, such as NRAGE (Salehi et al., 2000), and their interaction with 
P75. In this work, I demonstrate that the expression of NRAGE is affected by 
expression of Engrailed, comparable to that of P75. The increased expression of 
NRAGE in the EnDM ventral midbrain may be a contributing factor to the death of 
these neurons, especially since the high expression of NRAGE causes apoptosis via a 
JNK-mediated pathway, and a similar mechanism to cell death by high expression of 
P75 (Kendall et al., 2002). I also show that the expression of NRAGE in the wild type 
adult is limited to a subpopulation of mesDA neurons in the substantia nigra. The 
expression of NRAGE in the EnDM E12 mesDA neurons and in EnHT P20 mice 
remains to be examined. 
 
5- The Survival Effect of BDNF, NT4 and NT3 in EnDM mesDA 
Neurons, by Inhibition of P75 
 
To induce their most prominent function, survival, neurotrophins bind to their cognate 
Trk receptors (Lu et al., 2005). Our results show that the survival of Engrailed-
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deficient mesDA neurons by neurotrophins is dependent upon presence of Trk 
receptors and although a P75 ligand, in absence of TrkA, NGF does not change the 
rate of survival. Contrary to the primary mesDA neurons, in experiments with PC12 
cell lines, which do express TrkA, application of NGF can protect the cells against 
MPP+ treatment (Shimoke and Chiba, 2001). P75 and Trk receptors have been viewed 
as antagonizing partners and the rescue effect of BDNF, NT4 and NT3, in presence of 
TrkB and TrkC, is in line with previous findings showing that the P75 mediated 
cytotoxicity can be counteracted by Trk signaling(Davey and Davies, 1998). Our data 
also show that while the difference between the survival effect of NT4 and BDNF is 
minimal, NT3 is less effective in preventing the EnDM mesDA neurons. This is in 
agreement with previous findings, showing that NT4 and BDNF are functionally 
redundant and knocking in NT4 into the BDNF locus can reverse many of the 
phenotypes due to BDNF deficiency (Fan et al., 2000). It has been also implicated 
before that the NT3 (in comparison to BDNF or NT4) is less potent, as a survival 
factor for mesDA neurons  (Altar et al., 1994; Haque et al., 1996).  
The survival effect of neurotrophins can be due to activation of an intrinsic mechanism 
within the mesDA neurons or due to an indirect effect due to increased survival of the 
surrounding cells. The Kd value for binding affinity of neurotrophins to P75 or Trk is 
between 1 and 10nM (Barker, 2004). Since the Kd of 2.5nM, calculated from the linear 
dose-response trend-line of the survival effect of BDNF, corresponds to the known 
affinity of neurotrophins to P75 and Trk receptors, I conclude that the survival effect 
of neurotrophins is attributable to direct binding to the receptors on the surface of 
mesDA neurons as opposed to an indirect interaction with the neighboring cells, which 
would be reflected by a different Kd value. This is consistent with the concept that the 
Engrailed genes are cell-autonomously required for the survival of these 
neurons(Alberi et al., 2004). 
 
6- Activity of Erk1/2 is required for Survival of mesDA Neurons 
 
It is likely that absence of the Engrailed genes in E12 primary neurons, in absence of 
expression of neurotrophins, introduces a neurotrophin dependency by increasing the 
expression of P75. Since death of the neurons is a result of this unsatisfied requirement 
for neurotrophins, and addition of BDNF, NT3 and NT4 inhibits cell death, it is 
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possible that the downstream effectors of neurotrophins are differentially affected in 
EnDM versus En2-/- mesDA neurons. The activation of Erk1/2 in the wild type-like 
neurons as opposed to EnDM mesDA neurons, confirms this hypothesis. Addition of 
BDNF, NT4, NT3 and siRNA knockdown of P75 induced the activity of Erk1/2 in 
EnDM mesDA neurons, while GDNF and other neutral (to EnDM neurons) neurotrophic 
factors had no effect. On the other side, addition of 1µM U0126, an inhibitor of the 
upstream MAPKK of Erk1/2 pathway, Mek1/2 (Duncia et al., 1998), to the wild type-
like cultures for 72 hours, is lethal to mesDA neurons, suggesting that the sustained 
activation of Erk1/2 is required for their survival. While addition of a lower 
concentration, 400nM, of this inhibitor was not toxic to the En2-/- mesDA neurons, it 
significantly reduced the rescue effect of all survival factors, BDNF, NT4, NT3, Rex 
and siRNA knockdown of P75. This shows that Erk1/2 pathway is part of the natural 
survival machinery of mesDA neurons, which is disrupted by ablation of the Engrailed 
genes and addition of neurotrophins and functional inhibition of P75, puts in place a 
compensatory mechanism, which up to some degree makes up for this deficiency. 
Since the inhibition of Erk1/2, at this dose, did not affect the survival of wild type 
cultures, it is possible that deactivation of Erk1/2, although an important component of 
the death pathway, is not the sole arbitrator of death in absence of the Engrailed genes 
and high level of expression of P75. 
Erk1/2 and the two other MAPK pathways, JNK and P38, have opposing functions in 
vivo. While JNK and p38 participate in stress responses and, often, trigger apoptosis, 
Erk1/2 signaling regulates cell proliferation, differentiation and survival (Xia et al., 
1995). With regard to neurotrophins, P75 and Trk receptors, phosphorylation of 
Erk1/2, has been attributed to the kinase activity of Trk receptors at two 
phosphorylation sites, Shc and PLC gamma, caused by addition of neurotrophins 
(Atwal et al., 2000; Hu and Koo, 1998; Obermeier et al., 1994), whereas the high 
expression of P75 causes cell death by activation of JNK pathway (Bhakar et al., 
2003). In this study, I show that the activation of Erk1/2 is also controlled by 
expression of P75 and its activity increases when P75 is knocked down. The inhibition 
of activation of Erk1/2 in presence of P75 may be due to the opposing functions of P75 
and the Trk receptors or direct association of P75 to Erk or the upstream molecules of 
the MAPK pathway (Blochl et al., 2004; Volente et al., 1993). The direct binding to 
P75 can be excluded as the cause of inhibition of Erk1/2, since the MEK inhibition 
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diminished the rescue effect of siRNA knockdown of P75, its inhibition by Rex or 
addition of BDNF.  
Since the activation of Erk1/2 can also cause cell death (Subramaniam et al., 2004), the 
general role of Erk1/2 is still controversial and in neurotoxin-treated mesDA neurons, 
both pro-apoptotic and pro-survival roles have been implicated (Gomez-Santos et al., 
2002; Jiang and Yu, 2005). In mesDA neurons, I detected long term (more than 72 
hours), cytoplasmic activation of Erk1/2, only in the surviving, wild type-like neurons. 
Furthermore, the reduced activity of Erk1/2 by application of neurotoxins in MN9D 
cells and in primary mesDA neurons, death of the neurons by specific inhibition of 
Erk1/2, and mediating role of Erk1/2 with regard to survival inducing factors in EnDM 
neurons, i.e. neurotrophins and inhibition of P75, all support a pro-survival role for the 
Erk1/2 in mesDA neurons. 
 
7- Conclusions 
 
The ultimate question of PD is the issue of specific vulnerability of nigral DA neurons. 
 
 
Figure-1: Engrailed genes regulate P75 expression and determine stability of mitochondria. P75 
cell death signal in Engrailed deficient mesDA neurons is mediated by the suppression of the pro-
survival Erk1/2 activity. The cell death signal can be counteracted by TrkB/C-specific neurotrophins. 
Loss of Engrailed expression also leads to instability of mitochondrial membrane, and increased 
sensitivity to mitochondrial damage by (for example) MPTP. 
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The added sensitivity of nigral neurons to cell death is manifest in knockout studies of 
transcription factors, such as Pitx3, Nurr1, and the Engrailed genes, showing that the 
neurons in substantia nigra are especially vulnerable and the most affected by lack of 
these genes. The specificity of the effect of absence of these transcription factors to 
nigral neurons suggests that the causes for vulnerability lies within the expression 
profile of these neurons. The prime example of differential loss of nigral neurons in 
absence of transcription factors is the EnHT mice, where the PD-like phenotypes are 
resembled the most. Therefore, study of the mechanisms underlying survival and 
death, in presence or absence of the Engrailed genes, may provide direct hints in 
understanding the root cause of PD. In this study, I show that mitochondrial 
vulnerability and regulation of expression of P75 contribute to death of the Engrailed-
deficient mesDA neurons. The former is related to oxidative stress and to production 
of ROS, evident from the differential sensitivity of EnHT versus En2-/- mesDA neurons 
to MPTP treatment. The latter determines the activity of Erk1/2. The two mechanisms 
may be connected, since pharmacological inhibition of Erk1/2 increases the sensitivity 
to ROS(Yoon et al., 2002). The evidence, such as higher vulnerability of EnHT mesDA 
neurons to MPTP treatment, activation of caspase-9 in postnatal, dying nigral EnHT 
neurons, and the elevated expression of P75 in the ventral midbrain of EnHT embryos, 
indicate that the same mechanism may be the cause of slow, progressive PD-like 
degeneration of nigral DA neurons in the EnHT mice and therefore, abnormally low 
Engrailed or high P75 expression may be risk factors for PD. 
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Glossary 
 
AADC   l-Aromatic amino acid decarboxylase 
AIF   Apoptosis inducing factor 
Akt   Serine-threonine protein kinase 
AMPA   α-amino-3-hydroxy-5-methyl4-isoxazole-propionic acid 
AP   Anterior-posterior 
Apaf-1   Apoptosis protease activator factor-1 
ATP    Adenosine Triphosphate 
BDNF   Brain-derived neurotrophic factor 
BH   Bcl-2 homology domain 
BME    Basal medium eagle 
BMP    Bone morphogen protein 
BrdU    5-Bromo-2´-deoxyuridine 
cAMP   Cyclic adenosine monophosphate 
CC   Chelerythrine Chloride 
cDNA   Complementary deoxyribonucleic acid 
cGMP   Cyclic guanine monophosphate 
CNS    Central nervous system 
CREB    cAMP response element binding protein 
DA    Dopamine 
DAPI    4´,6-Diamidino-2-phenydole dilactate 
DAT    Dopamine transporter 
DNA    Deoxyribonucleic acid 
DMEM   Dulbecco modified eagle medium 
dNTP    Desoxyribonucleotide 
DV    Dorsal-ventral 
E    Embryonic day 
EDTA   Ethylene diamine tetracetic acid 
En    Engrailed 
EnDM    En1-/-;En2-/- 
EnHT   En1+/-;En2-/- 
En1    Engrailed-1 
En2    Engrailed-2 
Erk   Extracellular signal regulated kinase 
FGF    Fibroblast growth factor 
FBS    Fetal bovine serum 
FITC   Fluorescein isothiocyanate 
FP    Floor plate 
GABA   γ-aminobutyric acid 
GFP   Green fluorescent protein 
GP    Globus pallidus 
GDNF   Glial cell line derived factor 
HB    Homogenization buffer 
HH    Hambuurger Hamilton stage 
IgG   Immunoglobulin G 
IL-1    Interleukin-1 
L-15    Leibowitz medium-15   
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MAO    Monoamine oxidase 
MAPK   Mitogen-activated protein kinase 
MEK   MAPKK/ERK kinase 
MHB   Mid-hindbrain boundary 
MPT   Mitochondrial permeability transition 
MPDP+   1-methyl-4-phenyl-2,3-dihydropyridinium 
MPP+    1-methyl-4-phenylpyridinium 
MPTP    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NCS    Newborn calf serum 
NGF    Nerve growth factor 
NT3    Neurotrophin-3 
NT4   Neurotrophin-4 
6-OHDA   6-hydroxydopamine 
P75    Neurotrophin receptor p75/Ngfr 
Park-1   Parkin-1 
Park-2   Parkin-2 
PC12   Rat pheochromocytoma cell line 
PCR    Polymerase chain reaction 
PBS    Phosphate buffer saline 
PD    Parkinson’s disease 
PFA    Paraformaldehyde 
PI3K   Phosphatidylinositol-3-kinase 
Pitx3   Paired-like homeodomain transcription factor 
PKA   cAMP-dependent protein kinase 
PKC   Protein kinase C 
PNS   Peripheral nervous system 
RNA    Ribonucleic acid 
ROS   Reactive oxygen species 
RRF    Retrorubral field 
RT    Reverse transcriptase 
Shh    Sonic Hedgehog 
si    Small interfering 
SN    Substantia nigra 
SNpc    Substantia nigra pars compacta 
SNpl    Substantia nigra pars lateralis 
SNpr    Substantia nigra pars reticulata 
SOD    Superoxide dismutase 
TH   Tyrosine hydroxilase 
TGF    Transforming growth factor 
TNF    Tumor necrosis factor 
TNFR    Tumor necrosis factor receptor 
Trk   Tyrosine kinase receptor 
TUNEL   Tdt-mediated dUTP nick end labeling 
UTP    Uracyl triphosphate 
VMAT   Vescucular monoamine transporter 
VTA    Ventral tegmental area 
zVAD-fmk   Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
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Index 
 
A 
AADC, 8, 18 
acetic anhydride, 45, 47 
acetylation mix, 45, 47 
AHD2, 10 
AIF, 21, 24, 28, 29, 57, 82, 83 
akinesia, 13, 15, 17 
Akt, 63 
Alzheimer’s disease, 15 
annealing, 40, 41 
ANT, 22 
anterioposterior, 4 
Apaf-1, 24 
Aphakia, 10 
apomorphine, 17 
Apoptosis Activator-2, 54 
ATP, 20, 72 
AVID, 48 
axonal beadings, 69 
 
B 
Bad, 23 
Bak, 23 
basal ganglia, 7, 15, 16, 19 
Bax, 22, 23, 25, 28, 50, 85 
Bcl-2, 3, 22, 23, 24, 25, 28, 30, 31, 50, 51, 57, 82,  
         84, 85 
Bcl-w, 23 
Bcl-XL, 3, 23, 25, 28, 30, 51, 57, 83, 84 
BDNF, 3, 29, 30, 32, 33, 63, 65, 67, 86, 87, 88, 89 
BH, 23 
BH3-only, 3, 23, 24, 31 
Bid, 23, 24 
Bim, 23 
Bio-Rad-550 Microplate reader, 39 
BMP, 3 
Bok, 23 
bone morphogenic protein, 3 
borate buffer, 35 
bradykinesia, 13, 15 
 
C 
CAD, 25 
caspase-3, 13, 21, 24, 28, 29, 49, 52, 84 
caspase-8, 21, 24 
caspase-9, 22, 24, 25, 28, 49, 52, 54, 82, 91 
catecholamine, 18, 19 
caudate putamen, 13 
CD95, 21, 26 
Cerberus, 4 
chelerythrine chloride, 51, 54, 84 
cholinergic, 15 
chordin, 4 
c-Jun, 29, 68, 69 
CNS, 6, 10, 29 
CNTF, 29 
complex-I, 2, 19, 20, 25, 28, 82, 83 
cyclic-AMP, 18 
cytochrome C, 2, 21, 22, 24, 25, 28, 29, 57, 69, 82,  
         83, 84 
 
D 
D1, 16, 18, 40, 69 
D2, 16, 19, 33 
DAB, 41 
DAPI, 42 
DARPP32, 19 
DAT, 7, 18, 20 
dementia, 15 
Denhardt’s, 45 
DEPC, 40 
depression, 15 
dicer, 40 
dickkopf, 4 
DIG, 44, 45, 71 
digoxygenin, 45 
DISC, 21, 24 
DMEM-F12, 35, 36 
DMSO, 37, 43 
DOPAC, 18 
DPX, 46 
Drosophila, 12 
DTT, 40, 44, 46, 47 
dysarthria, 15 
dysphagia, 15 
 
E 
ECL, 43 
ectoderm, 3, 5 
EDTA, 34, 36, 40, 42, 45, 47 
En2-/-, 2, 13, 34, 36, 51, 54, 58, 64, 70, 73, 84, 88,  
         91 
EnDM, 34, 49, 50, 58, 62, 63, 64, 65, 67, 70, 73, 82,  
         83, 84, 85, 86, 87, 88 
endoderm, 4 
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